Poly (alkyl oxazoline)-lipid conjugates and lipid particles containing the same

By using poly(alkyloxazoline)-lipid conjugates instead of PEG-lipid conjugates, the resulting lipid nanoparticles improved the effectiveness and tolerability of mRNA delivery, solved the problem of allergic reactions caused by PEG, and achieved better drug activity and immune response.

CN118900701APending Publication Date: 2024-11-05GENEVANT SCI GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380019479.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-31
Filing Date
2023-01-30
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The use of polyethylene glycol (PEG) as a polymer conjugate in existing lipid nanoparticles has caused allergic reactions in some people, affecting drug activity and tolerability. There is a need to develop an alternative polymer conjugate to maintain effective drug delivery properties and tolerability.

Method used

Poly(alkyloxazoline)-lipid conjugates are used to form lipid nanoparticles by combining them with cationic lipids, neutral lipids and sterols, which are used to encapsulate nucleic acids such as mRNA, replacing traditional PEG-lipid conjugates.

Benefits of technology

It improved the effectiveness and tolerability of nucleic acid delivery, reduced nonspecific activity, decreased cytokine levels and antibody response, improved the clearance rate in plasma, and enhanced immunogenicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004969900440000021
    Figure BDA0004969900440000021
  • Figure BDA0004969900440000031
    Figure BDA0004969900440000031
  • Figure BDA0004969900440000101
    Figure BDA0004969900440000101
Patent Text Reader

Abstract

The present disclosure provides poly (alkyl oxazoline)-lipid conjugates, lipid particles comprising such conjugates, and methods of administering the lipid particles for nucleic acid delivery to a cell or subject.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 305,211, filed on January 31, 2022, the disclosure of which is hereby incorporated by reference in its entirety for all purposes. Background Art

[0003] along with With the advent of the mRNA-LNP COVID vaccine, lipid nanoparticles (LNPs) have become a mainstream drug form. LNPs typically have four different lipid components, including cationic lipids, non-cationic lipids (such as phospholipids and sterols), and polymer-conjugated lipids. Each plays a specific role, and they are carefully assembled in specific proportions to produce a highly effective and well-tolerated delivery vehicle.

[0004] Cationic lipids become positively charged at acidic pH, promoting the encapsulation of negatively charged nucleic acid (e.g., mRNA) payload during particle formation. After cellular uptake of LNP, it further drives endosomal fusion and cytoplasmic release of payload. Phospholipids and cholesterol are generally referred to as structural lipids, and concentration is selected to optimize particle size, encapsulation and stability. Polymer-conjugated lipids control particle size during formation, and prevent particle aggregation by making LNP space stable. It is located on the surface of the particle, and the hydrophilic polymer is oriented outwards, bordering with the aqueous environment, and the lipid component is buried in the particle to fix it in place.

[0005] Over the past few decades of developing lipid particles for nucleic acid delivery, the polymer of choice has been poly(ethylene glycol) (PEG) for the polymer-conjugated lipid component. PEG-lipids have been successfully used in several approved nucleic acid-containing LNPs, including the COVID-19 vaccine. and SpikeVax. However, due to exposure to PEG in other products (such as cosmetics), a small number of people may still produce antibodies that recognize and bind to PEG, leading to allergies and loss of drug activity (Judge et al., Mol Ther. 2006, 13 (2): 328-37). Shortly after the U.S. Food and Drug Administration (FDA) issued the emergency use authorization for the above COVID vaccines, anaphylactoid reactions after administration began to be reported (Shimabukuro et al., JAMA. 2021, 325 (11): 1101-1102). Although the cause of these cases has not yet been proven, some people have suggested that this may be due to the inclusion of PEG in these products. Therefore, there is a need to form alternative polymers with effective particles with desired activity and tolerability characteristics. The present disclosure addresses this need and other needs. Summary of the invention

[0006] Provided herein are poly(alkyloxazoline)-lipid conjugates according to Formula I:

[0007]

[0008] and pharmaceutically acceptable salts thereof, wherein:

[0009] Subscript n is an integer from 10 to 100;

[0010] Each R 1 Independently C 1-6 alkyl;

[0011] Each R 2 are independently selected from hydrogen, C 1-6 Alkyl and C 1-6 acyl groups; and

[0012] (i) Z is -S(CH2)2C(O)-, and

[0013] R 3 Selected from -NR 3a R 3b 、-NR 3a CH2CH(R 3b )2、-CH(R 3b )2 and -CH2CH(R 3b )2;

[0014] or

[0015] (ii) Z is selected from -Z 1 -OC(O)-、-Z 1 -NHC(O)-、-Z 1 -S(O)2- and -Z 1 -OCH2-,

[0016] Z 1 is selected from the group consisting of a covalent bond, an oligo(ethylene glycol) diradical and a poly(ethylene glycol) diradical, and

[0017] R 3 Selected from -NR 3a R 3b and -CH(R 3b )2;

[0018] Each R 3a and R 3b are independently selected from hydrogen, C 6-22 Alkyl, C 6-22 Alkenyl and C 6-22 Alkynyl, where R 3a and R 3bOne or more non-adjacent CH2 groups in are optionally and independently replaced by oxygen,

[0019] The condition is that at least one R 3a or R 3b Selected from C 6-22 Alkyl, C 6-22 Alkenyl and C 6-22 Alkynyl, where R 3a or R 3b One or more non-adjacent CH2 groups in are optionally and independently replaced by oxygen.

[0020] In some embodiments, R 1 In some embodiments, R 1 is methyl. In some embodiments, each R 1 Independently selected from methyl and ethyl.

[0021] In some embodiments, the subscript n is an integer from about 15 to about 55. In some embodiments, the poly(alkyloxazoline) portion of the conjugate has a number average molecular weight of from about 2,000 Da to about 5,000 Da.

[0022] In some embodiments, the poly(alkyloxazoline)-lipid conjugate has a structure according to Formula IIa:

[0023]

[0024] or a pharmaceutically acceptable salt thereof, wherein:

[0025] R 2 is selected from hydrogen and methyl;

[0026] R 3a Selected from hydrogen, C 12-18 Alkyl and C 12-18 alkenyl; and

[0027] R 3b Selected from C 12-18 Alkyl and C 12-18 Alkenyl.

[0028] In certain aspects, the disclosure provides lipid nanoparticles comprising poly (alkyl oxazoline)-lipid conjugates described herein (e.g., according to Formula I). ​​In some embodiments, the lipid nanoparticles further comprise cationic lipids, neutral lipids (e.g., phospholipids), sterols (e.g., cholesterol) or combinations thereof. In some embodiments, the lipid nanoparticles further comprise nucleic acids. In certain embodiments, the nucleic acids include RNA (e.g., mRNA). In some embodiments, the nucleic acids are completely encapsulated in the lipid nanoparticles. In some embodiments, the lipid nanoparticles have an average diameter of 40nm to 150nm.

[0029] In some aspects, the present disclosure provides a lipid nanoparticle comprising:

[0030] (a) nucleic acids;

[0031] (b) a cationic lipid, said cationic lipid accounting for 30 mol % to 80 mol % of the total lipids present in said lipid nanoparticle;

[0032] (c) neutral lipids;

[0033] (d) sterols; and

[0034] (e) a poly(alkyloxazoline)-lipid conjugate, wherein the poly(alkyloxazoline)-lipid conjugate accounts for 0.1 mol% to 10 mol% of the total lipids present in the lipid nanoparticle.

[0035] In some embodiments, the cationic lipid accounts for 40 mol% to 70 mol% of the total lipids present in the lipid nanoparticle. In some embodiments, the cationic lipid accounts for 45 mol% to 65 mol% of the total lipids present in the lipid nanoparticle. In some embodiments, the cationic lipid accounts for 45 mol% to 60 mol% of the total lipids present in the lipid nanoparticle. In some embodiments, the cationic lipid accounts for 50 mol% to 60 mol% of the total lipids present in the lipid nanoparticle.

[0036] In some embodiments, the neutral lipids comprise 3 mol% to 20 mol% of the total lipids present in the lipid nanoparticles. In some embodiments, the neutral lipids comprise 5 mol% to 15 mol% of the total lipids present in the lipid nanoparticles. In some embodiments, the neutral lipids comprise 8 mol% to 12 mol% of the total lipids present in the lipid nanoparticles. In certain embodiments, the neutral lipids comprise phospholipids.

[0037] In some embodiments, the sterol accounts for 10 mol% to 60 mol% of the total lipids present in the lipid nanoparticle. In some embodiments, the sterol accounts for 20 mol% to 50 mol% of the total lipids present in the lipid nanoparticle. In some embodiments, the sterol accounts for 30 mol% to 40 mol% of the total lipids present in the lipid nanoparticle. In certain embodiments, the sterol comprises cholesterol.

[0038] In some embodiments, the poly(alkyloxazoline)-lipid conjugate comprises 0.1 mol% to 5 mol% of the total lipid present in the lipid nanoparticle. In some embodiments, the poly(alkyloxazoline)-lipid conjugate comprises 0.5 mol% to 3 mol% of the total lipid present in the lipid nanoparticle. In certain embodiments, the poly(alkyloxazoline)-lipid conjugate comprises a poly(alkyloxazoline)-lipid conjugate described herein (e.g., according to Formula I).

[0039] In a specific embodiment, the cationic lipid accounts for 50 mol% to 60 mol% of the total lipids present in the lipid nanoparticles, the neutral lipid accounts for 8 mol% to 12 mol% of the total lipids present in the lipid nanoparticles, the sterol accounts for 30 mol% to 40 mol% of the total lipids present in the lipid nanoparticles, and the poly(alkyloxazoline)-lipid conjugate accounts for 0.5 mol% to 3 mol% of the total lipids present in the lipid nanoparticles.

[0040] In some embodiments, the nucleic acid comprises RNA. In certain embodiments, the RNA comprises mRNA. In some embodiments, the nucleic acid is completely encapsulated in the lipid nanoparticle. In some embodiments, the lipid nanoparticle has an average diameter of 40nm to 150nm.

[0041] In certain aspects, the disclosure provides a pharmaceutical composition comprising a lipid nanoparticle described herein and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is formulated for intravenous administration, intramuscular administration, pulmonary administration, intracerebral administration, intrathecal administration, or intranasal administration.

[0042] In some aspects, the disclosure provides methods for introducing nucleic acids into cells, the methods comprising contacting the cells with lipid nanoparticles or pharmaceutical compositions described herein. In other aspects, the disclosure provides methods for delivering nucleic acids to subjects, the methods comprising administering lipid nanoparticles or pharmaceutical compositions described herein to the subjects. In further aspects, the disclosure provides methods for preventing or treating diseases or conditions in subjects in need, the methods comprising administering lipid nanoparticles or pharmaceutical compositions described herein to the subjects. In some embodiments, the disease or condition is a viral infection, a liver disease or condition, a lung disease or condition, a disease or condition of the CNS, or a cancer.

[0043] Other objects, features and advantages of the present disclosure will become apparent to those skilled in the art from the following detailed description. DETAILED DESCRIPTION

[0044] I. Introduction

[0045] We have designed novel polymer-conjugated lipids comprising poly(alkyloxazoline) polymers such as poly(2-ethyl-2-oxazoline) (PEOZ). We have conjugated the polymers to various lipid moieties, yielding a range of poly(alkyloxazoline)-lipid conjugates. Such lipid conjugates have been formulated into lipid nanoparticles containing nucleic acid such as mRNA payloads and characterized as described in the Examples herein.

[0046] We have found that the lipid conjugates described herein form effective lipid nanoparticles with favorable physicochemical properties, such as desired particle size and low polydispersity and high encapsulation efficiency of nucleic acid (e.g., mRNA) payload. In vivo studies have shown that the lipid nanoparticle formulations described herein mediate high levels of activity at the target site, showing equivalent or improved activity compared to PEG-lipid conjugates with lower nonspecific (off-target) activity. Compared with PEG-lipid conjugates, the lipid nanoparticle formulations described herein induce similar or lower cytokine levels and therefore have more favorable immunostimulatory properties. Compared with PEG-lipid conjugates, the lipid nanoparticle formulations described herein also show improved clearance rates from plasma, and therefore have shorter residence times in plasma to mitigate antibody responses during repeated dose administration. Additional in vivo studies have shown that the lipid nanoparticle formulations described herein can be successfully incorporated into vaccine platforms to deliver mRNA encoding antigens, thereby inducing antigen-specific immunogenicity to a similar or greater degree than PEG-lipid conjugates. Thus, lipid nanoparticles comprising poly(alkyloxazoline)-lipid conjugates provide advantageous activity and tolerability characteristics over particles containing PEG-lipid conjugates.

[0047] II. Definitions

[0048] As used herein, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a conjugate" optionally includes combinations of two or more such molecules, and the like.

[0049] As used herein, when used to modify a numerical value or an amount specified in a range, the terms "about" and "approximately" represent the numerical value and reasonable deviations from the value known to those skilled in the art, for example, ±20%, ±10% or ±5% within the intended meaning of the value.

[0050] As used herein, the term "alkyl" by itself or as part of another substituent refers to a straight or branched chain saturated aliphatic group having the indicated number of carbon atoms. The alkyl group may contain any number of carbon atoms, such as C 1-2 , C 1-3 , C 1-4 , C 1-5 , C 1-6 , C 1-7 , C 1-8 , C 1-9 , C 1-10 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 3-4 , C 3-5 , C 3-6 , C 4-5 , C 4-6 and C 5-6 For example, C 1-6 Alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc. Alkyl may also refer to an alkyl group having up to 20 carbon atoms, such as, but not limited to, heptyl, octyl, nonyl, decyl, etc.

[0051] As used herein, the term "alkenyl," by itself or as part of another substituent, refers to an alkyl group having at least one carbon-carbon double bond.

[0052] As used herein, the term "alkynyl," by itself or as part of another substituent, refers to an alkyl group having at least one carbon-carbon triple bond.

[0053] As used herein, the term "acyl," by itself or as part of another substituent, refers to the moiety -C(O)R, where R is an alkyl group.

[0054]

[0046] As used herein, the terms "halo" and "halogen," by themselves or as part of another substituent, refer to a fluorine, chlorine, bromine, or iodine atom.

[0055] As used herein, the term "amino" refers to the moiety -NR2, wherein each R group is H or an alkyl group. The amino moiety can be ionized to form the corresponding ammonium cation.

[0056] As used herein, the term "sulfonyl" refers to the moiety -SO2R, where the R group is alkyl, haloalkyl, or aryl (e.g., phenyl, toluoyl, naphthyl, etc.). The amino moiety can be ionized to form the corresponding ammonium cation. "Alkylsulfonyl" refers to the amino moiety, where the R group is an alkyl.

[0057] As used herein, the term "hydroxy" refers to the moiety -OH.

[0058] As used herein, the term "salt" refers to a compound comprising at least one cation (e.g., an organic cation or an inorganic cation) and at least one anion (e.g., an organic anion or an inorganic anion). According to the acid salt of the lipid of the present disclosure, include but are not limited to inorganic acid salts (e.g., salts formed using hydrochloric acid, hydrobromic acid, phosphoric acid, etc.), organic acid salts (e.g., salts formed using acetic acid, propionic acid, glutamic acid, citric acid, etc.) and quaternary ammonium salts (e.g., salts formed using iodomethane, iodoethane, etc.). Acidic functional groups can be contacted with a base to provide basic salts, such as alkali metal salts and alkaline earth metal salts (e.g., sodium, lithium, potassium, calcium and magnesium salts), and ammonium salts (e.g., ammonium, trimethyl-ammonium, diethylammonium and tris (hydroxymethyl)-methyl-ammonium salts).

[0059] In some embodiments, the neutral form of the compound can be regenerated by contacting the salt with a base or acid and separating the parent compound in a conventional manner (if necessary). In some embodiments, the parent form of the compound can be different from the various salt forms in certain physical properties (such as solubility in polar solvents), but otherwise the salt form can be equivalent to the parent form of the compound.

[0060] "Pharmaceutically acceptable" means that the excipient is compatible with the other ingredients of the formulation and is not harmful to the recipient thereof. It should be understood, for example, that pharmaceutically acceptable excipients and salts are non-toxic. Useful pharmaceutical excipients include, but are not limited to, solvents, diluents, pH adjusters, and solubilizing agents.

[0061] The term "nucleic acid" refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in single-stranded or double-stranded form, and includes DNA and RNA. DNA (e.g., ssDNA or dsDNA) can be, for example, an antisense molecule, plasmid DNA, precondensed DNA, PCR product, vector (P1, PAC, BAC, YAC, artificial chromosome), expression module, chimeric sequence, chromosomal DNA or derivatives and combinations of these groups. RNA (e.g., ssRNA or dsRNA) can be, for example, messenger RNA (mRNA), interfering RNA (e.g., small interfering RNA (siRNA), short hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA)), microRNA (miRNA), guide RNA (gRNA), self-amplification RNA, tRNA, rRNA, viral RNA (vRNA) and combinations thereof. In some embodiments, nucleic acid is a plasmid from which RNA such as mRNA or interfering RNA is transcribed. The term includes backbone residues or linked nucleic acids containing known nucleotide analogs or modifications, which are synthetic, naturally occurring and non-naturally occurring, and have binding properties similar to reference nucleic acids. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methylphosphonates, chiral methylphosphonates, 2'-O-methyl ribonucleotides and peptide-nucleic acids (PNAs). Unless otherwise indicated, a particular nucleic acid sequence also implicitly includes conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, interspecies homologs, SNPs and complementary sequences as well as sequences explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is replaced by mixed bases and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res., 19:5081 (1991); Ohtsuka et al., J. Biol. Chem., 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes, 8:91-98 (1994)). "Nucleotide" contains sugar deoxyribose (DNA) or ribose (RNA), a base and a phosphate group. Nucleotides are linked together by phosphate groups. "Bases" include purines and pyrimidines, which further include the natural compounds adenine, thymine, guanine, cytosine, uracil, inosine and natural analogs, and synthetic derivatives of purines and pyrimidines, which include but are not limited to modifications that place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkyl halides.

[0062] As used herein, the term "lipid particle", "lipid nanoparticle" or "LNP" refers to a particle comprising a poly (alkyl oxazoline) -lipid conjugate. The lipid particle may comprise additional lipid components, such as a cationic lipid and one or more non-cationic lipids (e.g., phospholipids and / or sterols), and may further comprise a nucleic acid, wherein the nucleic acid may be encapsulated within the particle. In one embodiment, at least 50% of the nucleic acid is encapsulated within the particle; in one embodiment, at least 75% of the nucleic acid is encapsulated within the particle; in one embodiment, at least 90% of the nucleic acid is encapsulated within the particle; in one embodiment, the nucleic acid is completely encapsulated within the particle. Lipid particles are very useful for systemic applications because they can exhibit extended circulation life after intravenous injection, they can accumulate at distal sites (e.g., sites physically separated from the site of administration), and they can mediate the expression of transfected genes or silence the expression of target genes at these distal sites. Lipid granule has the average diameter of about 40nm to about 150nm, about 50nm to about 150nm, about 60nm to about 130nm, about 70nm to about 110nm, about 60nm to about 100nm, about 50nm to about 80nm, about 60nm to about 80nm, about 60nm to about 90nm or about 70nm to about 90nm conventionally, and is nontoxic substantially.In addition, when nucleic acid was present in lipid granule, nucleic acid had resistance to the degraded of nuclease in aqueous solution.Lipid granule and preparation method thereof are disclosed in for example U.S. Patent Publication No. 2004 / 0142025 and 2007 / 0042031.

[0063] As used herein, the term "lipid encapsulated" refers to providing lipid particles having a nucleic acid (eg, mRNA) that is fully encapsulated, partially encapsulated, or both. In one embodiment, the nucleic acid is fully encapsulated within the particle.

[0064] The term "cationic lipid" refers to a lipid species that carries a net positive charge at a selected pH, such as an acidic pH or physiological pH. The non-limiting examples of cationic lipids are described in detail herein. In some cases, the cationic lipid comprises an ionizable primary amine, a secondary amine or a tertiary amine (e.g., a titratable pH) head group. In one embodiment, the cationic lipid promotes the encapsulation of a negatively charged nucleic acid (e.g., mRNA) payload during particle formation. In one embodiment, the cationic lipid drives endosome fusion and cytoplasm release of payload after cell uptake of LNP.

[0065] The term "non-cationic lipid" includes neutral lipids, sterols and negatively charged anionic lipids in the form of neutral zwitterions at selected pH (e.g., physiological pH). The limiting examples of non-cationic lipids are described in detail herein. Neutral lipids include, for example, phospholipids, such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylcholine (DOPC), distearoylphosphatidylcholine (DSPC) and dilinoleoylphosphatidylcholine (DLPC). Sterol includes, for example, cholesterol and derivatives thereof, such as cholestanol, cholestanone, cholestenone, fecal sterol, cholesteryl-2'-hydroxyethyl ether and cholesteryl-4'-hydroxybutyl ether. Anionic lipids include, for example, phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-dodecanoylphosphatidylethanolamine, N-succinylphosphatidylethanolamine, N-glutarylphosphatidylethanolamine, lysylphosphatidylglycerol, palmitoylphosphatidylglycerol (POPG), and other anionic modifying groups attached to neutral lipids.

[0066] As used herein, "distal site" refers to a physically separate site that is not limited to adjacent capillary beds, but includes sites widely distributed within a subject's body.

[0067] "Serum stable" in relation to lipid particles described herein means that the particles do not significantly degrade after exposure to serum or nuclease assays that would significantly degrade free DNA or RNA. Suitable assays include, for example, standard serum assays, DNAse assays, or RNAse assays.

[0068] " Systemic delivery " used herein refers to the delivery of lipid particles, which causes a wide biodistribution of nucleic acids such as mRNA in a subject. Systemic delivery means useful amount, preferably the nucleic acid of therapeutic amount is exposed to the major part of health. In order to obtain a wide range of biodistribution, blood life is usually required so that nucleic acids will not be rapidly degraded or removed (e.g., by first-pass organs (liver, lungs, etc.) or by fast, non-specific cell binding) before arriving at the target site away from the application site. The systemic delivery of lipid particles can be carried out by any means known in the art, including, for example, intravenous, subcutaneous and intraperitoneal administration. In one embodiment, lipid particles are delivered intravenously.

[0069] As used herein, "local delivery" refers to the direct delivery of a nucleic acid, such as mRNA, to a target site within a subject. For example, the nucleic acid can be delivered locally by direct injection into a disease site, such as a tumor, or other target sites, such as sites of inflammation, or target organs, such as the liver, heart, pancreas, kidneys, etc.

[0070] The terms "subject," "individual," and "patient," as used interchangeably herein, refer to mammals, including but not limited to humans, non-human primates, rodents (e.g., rats, mice, and guinea pigs), rabbits, cows, pigs, horses, and other mammalian species. In one embodiment, the subject, individual, or patient is a human.

[0071] III. Poly(alkyloxazoline)-lipid conjugates

[0072] Provided herein are poly(alkyloxazoline)-lipid conjugates according to Formula I:

[0073]

[0074] and pharmaceutically acceptable salts thereof, wherein:

[0075] Subscript n is an integer from 10 to 100;

[0076] Each R 1 Independently C 1-6 alkyl;

[0077] Each R 2 are independently selected from hydrogen, C 1-6 Alkyl and C 1-6 acyl groups; and

[0078] (i) Z is -S(CH2)2C(O)-, and

[0079] R 3 Selected from -NR 3a R 3b 、-NR 3a CH2CH(R 3b )2、-CH(R 3b )2 and -CH2CH(R 3b )2;

[0080] or

[0081] (ii) Z is selected from -Z 1 -OC(O)-、-Z 1 -NHC(O)-、-Z 1 -S(O)2- and -Z 1 -OCH2-,

[0082] Z 1 is selected from the group consisting of a covalent bond, an oligo(ethylene glycol) diradical and a poly(ethylene glycol) diradical, and

[0083] R 3 Selected from -NR 3a R 3b and -CH(R 3b )2;

[0084] Each R 3a and R 3b are independently selected from hydrogen, C 6-22 Alkyl, C 6-22 Alkenyl and C 6-22 Alkynyl, where R 3a and R 3b One or more non-adjacent CH2 groups in are optionally and independently replaced by oxygen,

[0085] The condition is that at least one R 3a or R 3b Selected from C 6-22 Alkyl, C 6-22 Alkenyl and C 6-22 Alkynyl, where R 3a or R 3b One or more non-adjacent CH2 groups in are optionally and independently replaced by oxygen.

[0086] In some embodiments, R 1 In some embodiments, R 1 is methyl. In some embodiments, each R 1 Independently selected from methyl and ethyl.

[0087] In some embodiments, the subscript n is an integer from about 15 to about 55. In some embodiments, the poly(alkyloxazoline) portion of the conjugate has a number average molecular weight of about 2,000 Da to about 5,000 Da. The molecular weight can be determined by any suitable method, including, for example, osmotic pressure, vapor pressure, light scattering, ultracentrifugation, or size exclusion chromatography. Using size exclusion chromatography with an appropriately calibrated column, the number average molecular weight M can be determined according to Equation 1 n :

[0088]

[0089] And the weight average molecular weight M can be determined according to Equation 2 w :

[0090]

[0091] Where W is the total weight of the polymer, W i is the weight of the ith polymer, M i is the molecular weight of the ith peak in the chromatogram, N i is a molecular weight N i The number of molecules, and H i is the height of the ith peak in the chromatogram.

[0092] In some embodiments, the poly(alkyloxazoline)-lipid conjugate has a structure according to Formula IIa:

[0093]

[0094] or a pharmaceutically acceptable salt thereof, wherein:

[0095] R 2 is selected from hydrogen and methyl;

[0096] R 3a Selected from hydrogen, C 12-18 Alkyl and C 12-18 alkenyl; and

[0097] R 3b Selected from C 12-18 Alkyl and C 12-18 Alkenyl.

[0098] In some embodiments, R 3a and R 3b C is independently selected from the poly(alkyloxazoline)-lipid conjugate according to Formula IIa 12-18 Alkyl and C 12-18 In some embodiments, R 3a and R 3b Independently C 12-18 In some embodiments, R in Formula IIa 3a and R 3b is n-dodecyl (lauryl), n-tridecyl, n-tetradecyl (myristyl), n-pentadecyl, n-hexadecyl (cetyl), n-heptadecyl or n-octadecyl (stearyl). In some embodiments, R in Formula IIa 3a is H and R 3b It is n-dodecyl (lauryl), n-tridecyl, n-tetradecyl (myristyl), n-pentadecyl, n-hexadecyl (cetyl), n-heptadecyl or n-octadecyl (stearyl).

[0099] In some embodiments, the poly(alkyloxazoline)-lipid conjugate has a structure according to Formula lib:

[0100]

[0101] or a pharmaceutically acceptable salt thereof, wherein:

[0102] R 2 is selected from hydrogen and methyl; and

[0103] Each R 3c Independently selected from C 12-18 Alkyl and C 12-18In some embodiments, R in Formula IIb is 3a and R 3b It is n-dodecyl (lauryl), n-tridecyl, n-tetradecyl (myristyl), n-pentadecyl, n-hexadecyl (cetyl), n-heptadecyl or n-octadecyl (stearyl).

[0104] The lipid conjugates can be synthesized using the methods described below and synthetic methods known in the field of synthetic organic chemistry or variations thereof. Preferred methods include, but are not limited to, those described in the working examples and the following schemes. The starting materials and reagents used to prepare the compounds of the present disclosure can be obtained from commercial suppliers or prepared by methods known to those skilled in the art according to the following processes described in references, such as Fieser and Fieser's Reagents for Organic Synthesis, Vol. 1-28 (Wiley, 2016); March's Advanced Organic Chemistry, 7 th Ed. (Wiley, 2013); and Larock's Comprehensive Organic Transformations, 2 nd Ed. (Wiley, 1999). If necessary, the starting materials and intermediates of the reaction can be separated and purified using conventional techniques including, but not limited to, filtration, chromatography, crystallization, distillation, etc. Such materials can be characterized using conventional means, including measuring physical constants and obtaining spectral data.

[0105] Conjugates according to Formula IIa and Formula IIb can be formed by reacting N-hydroxysuccinimidyl ester terminated polymers according to Formula III (synthesized as described, for example, in WO2008 / 106186) with various amines.

[0106]

[0107] In some embodiments, a carbamate-linked conjugate is provided wherein Z is -Z 1 -OC(O)-,Z 1 is selected from a covalent bond and a poly(ethylene glycol) diradical, and R 3 Yes - NR 3a R 3b. Carbamate-linked conjugates can be prepared as shown in the following scheme. Hydroxyl-terminated poly (alkyl oxazoline) is first reacted with bis (4-nitrophenyl) carbonate to provide carbonate-terminated poly (alkyl oxazoline), which can then be converted into a carbamate-linked product via reaction with a suitable amine. The reaction is usually carried out in the presence of a base such as potassium carbonate, sodium carbonate, sodium acetate, N,N-diisopropylethylamine, lutidine including 2,6-lutidine, triethylamine, tributylamine, pyridine, lithium diisopropylamide, 2,6-di-tert-butylpyridine, 1,8-diazabicycloundec-7-ene (DBU), etc.

[0108]

[0109] In some embodiments, a urea-linked conjugate is provided wherein Z is -Z 1 -NHC(O)-,Z 1 is a covalent bond, and R 3 Yes - NR 3a R 3b Urea-linked conjugates can be prepared as shown in the following scheme. First, the hydroxy-terminated poly(alkyloxazoline) is converted to an amine-terminated poly(alkyloxazoline) by reaction with phthalimide under Mitsunobu conditions and subsequent reduction with hydrazine. The terminal amine is then reacted with triphosgene and an amine HNR 3a R 3b reaction.

[0110]

[0111] In some embodiments, an amide-linked conjugate is provided wherein Z is -Z 1 -NHC(O)-,Z 1 is a covalent bond, and R 3 Yes -CH(R 3b)2. As shown in the following scheme, the amine-terminated poly(alkyloxazoline) prepared as described above can be acylated with a carboxylic acid to form an amide-linked conjugate. A coupling agent can be used to promote amide bond formation. Examples of suitable coupling agents include, but are not limited to, carbodiimides (e.g., N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), etc.), phosphonium salts (e.g., (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PyBOP); bromotris(dimethylamino)-phosphonium hexafluorophosphate (BroP); etc.); guanidine salts / urea salts (e.g. , O-(benzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU); 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU); 1-[(1-(cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylaminomorpholino)]uronium hexafluorophosphate (COMU); etc.) and propanephosphonic anhydride. The coupling agent can be used with a base and / or a catalyst, including but not limited to pyridine and dimethylaminopyridine (DMAP).

[0112]

[0113] In some embodiments, an ester-linked conjugate is provided wherein Z is -Z 1 -OC(O)-,Z 1 is a covalent bond, and R 3 Yes -CH(R 3b ) 2. Ester-linked conjugates can be prepared as shown in the following scheme using coupling agents for linking carboxylic acids to hydroxy-terminated poly(alkyloxazolines).

[0114]

[0115] In some embodiments, a sulfonamide-linked conjugate is provided wherein Z is -Z 1 -S(O)2-,Z 1 is a covalent bond, and R 3 Yes - NR 3a R 3b As shown in the following scheme, hydroxyl-terminated poly(alkyl oxazoline)s can be converted to sulfonyl chloride-terminated poly(alkyl oxazoline)s with thionyl chloride and sodium sulfite. The sulfonyl chloride-terminated poly(alkyl oxazoline)s can then be reacted with amines in the presence of a base to provide sulfonamide-linked conjugates.

[0116]

[0117] In some embodiments, an ether-linked conjugate is provided wherein Z is -Z 1-OCH2-, Z 1 is a covalent bond, and R 3 Yes -CH(R 3b )2. Ether-linked conjugates can be prepared as shown below. Hydroxyl-terminated poly(alkyl oxazoline)s can be converted into sulfonate-terminated poly(alkyl oxazoline)s, which react with an alcohol to form an ether-linked conjugate. Sulfonates can be used, including but not limited to methanesulfonates (methanesulfonates), trifluoromethanesulfonates (trifluoromethanesulfonates), benzenesulfonates (benzenesulfonates), toluenesulfonates (p-toluenesulfonates), and bromobenzenesulfonates (4-bromobenzenesulfonates).

[0118]

[0119] In some embodiments, in the carbamate-linked conjugate, urea-linked conjugate, amide-linked conjugate, ester-linked conjugate, sulfonamide-linked conjugate, or ether-linked conjugate, R 3a and each R 3b Independently selected from C 12-18 Alkyl and C 12-18 In some embodiments, R 3a and each R 3b Independently selected from C 12-18 Alkyl. 3a and R 3b It can be, for example, n-dodecyl (lauryl), n-tridecyl, n-tetradecyl (myristyl), n-pentadecyl, n-hexadecyl (cetyl), n-heptadecyl or n-octadecyl (stearyl). In some embodiments, R 3a is H and R 3b It is C 12-18 In some embodiments, two R 3b Independently selected from C 12-18 alkyl.

[0120] In some embodiments, a poly(alkyloxazoline)-poly(ethylene glycol) lipid conjugate is provided wherein Z is -Z 1 -S(CH2)2C(O)-、-Z 1 -OC(O)-、-Z 1 -NHC(O)-、-Z 1 -S(O)2- or -Z 1 -OCH2-, and Z 1 is an oligo(ethylene glycol) diradical or a poly(ethylene glycol) diradical. The oligo-(ethylene glycol) or poly-(ethylene glycol) portion of the conjugate may contain 2-200 ethylene glycol monomers. In some embodiments, the oligo-(ethylene glycol) or poly-(ethylene glycol) Z1 Contains an average of 3-100 ethylene glycol monomers (for example, such that Z 1 The number average molecular weight and / or weight average molecular weight is 0.025 to 5 kDa or 0.5 to 1 kDa). As shown below, the poly(ethylene glycol) can be functionalized with a terminal sulfonate group, which can then be used for the alkylation of a hydroxyl-terminated poly(alkyloxazoline) to form a poly(alkyloxazoline)-poly(ethylene glycol) copolymer. The desired lipid conjugates can then be prepared from the copolymer using various attachment strategies as described above.

[0121]

[0122] IV. Lipid Particles

[0123] In one aspect, lipid particles include poly (alkyl oxazoline) -lipid conjugates according to formula I. In some embodiments, the lipid particles further include cationic lipids, neutral lipids, sterols or combinations thereof. In some embodiments, the lipid particles further include nucleic acids. On the other hand, lipid particles include nucleic acids, cationic lipids, neutral lipids, sterols and poly (alkyl oxazoline) -lipid conjugates (for example, according to formula I). ​​In some embodiments, nucleic acids are completely encapsulated in the lipid portion of lipid particles so that the nucleic acids in the lipid particles are resistant to enzymatic degradation (for example, by nucleases or proteases) in aqueous solution. In some embodiments, lipid particles are substantially nontoxic to mammals (for example, people).

[0124] In certain embodiments, present disclosure provides lipid particle preparations comprising most or all lipid particles. In some embodiments, nucleic acid is completely encapsulated in the lipid part of lipid particles, so that about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 90% to about 100%, about 30% to about 95%, about 40% to about 95%, about 50% to about 95%, about 60% to about 95%, about 70% to about 95%, about 80% to about 100%, about 90% to about 100%, about 30% to about 95%, about 40% to about 95%, about 50% to about 95%, about 60% to about 95%, about 70% to about 95%, about 80% to about 95%, about 85% to about 95%, about 90% to about 95%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% (or any fraction or range therein) of the lipid particles have nucleic acid encapsulated therein.

[0125] In some embodiments, the lipid particles have an average diameter of about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, about 60 nm to about 100 nm, about 50 nm to about 80 nm, about 60 nm to about 80 nm, about 60 nm to about 90 nm, or about 70 nm to about 90 nm.

[0126] In some embodiments, the cationic lipid present in the lipid particle accounts for about 30mol% to about 80mol%, about 40mol% to about 80mol%, about 50mol% to about 80mol%, about 30mol% to about 70mol%, about 40mol% to about 70mol%, about 50mol% to about 70mol%, about 45mol% to about 80mol%, about 45mol% to about 70mol%, about 45mol% to about 65mol%, about 45mol% to about 60mol%, about 45mol% to about 55mol%, about 50mol% to about 65mol%, about 50mol% to about 60mol% or about 55mol% to about 65mol% of the total lipid present in the particle. In some embodiments, the cationic lipid present in the lipid particle accounts for about 40mol%, about 45mol%, about 50mol%, about 55mol%, about 60mol% or about 65mol% of the total lipid present in the particle.

[0127] In some embodiments, the neutral lipid (e.g., phospholipid) present in the lipid particle accounts for about 3 mol% to about 20 mol%, about 5 mol% to about 20 mol%, about 8 mol% to about 20 mol%, about 10 mol% to about 20 mol%, about 3 mol% to about 15 mol%, about 5 mol% to about 15 mol%, about 8 mol% to about 15 mol%, about 10 mol% to about 15 mol%, or about 8 mol% to about 12 mol% of the total lipid present in the particle. In some embodiments, the neutral lipid (e.g., phospholipid) present in the lipid particle accounts for about 5 mol%, about 6 mol%, about 7 mol%, about 8 mol%, about 9 mol%, about 10 mol%, about 11 mol%, about 12 mol%, about 13 mol%, about 14 mol%, or about 15 mol% of the total lipid present in the particle.

[0128] In some embodiments, the sterol (e.g., cholesterol) present in the lipid particles comprises about 10 mol% to about 60 mol%, about 20 mol% to about 60 mol%, about 30 mol% to about 60 mol%, about 40 mol% to about 60 mol%, about 20 mol% to about 50 mol%, about 30 mol% to about 50 mol%, about 35 mol% to about 50 mol%, about 40 mol% to about 50 mol%, about 20 mol% to about 45 mol%, about 25 mol% to about 50 mol%, about 30 mol% to about 50 mol%, about 35 mol% to about 50 mol%, about 40 mol% to about 50 mol%, about 20 mol% to about 45 mol%, about 25 Mol % to about 45 mol %, about 30 mol % to about 45 mol %, about 35 mol % to about 45 mol %, about 20 mol % to about 40 mol %, about 25 mol % to about 40 mol % or about 30 mol % to about 40 mol %. In some embodiments, the sterol (e.g., cholesterol) present in the lipid particles accounts for about 20 mol %, about 25 mol %, about 30 mol %, about 35 mol %, about 40 mol %, about 45 mol % or about 50 mol % of the total lipid present in the particles.

[0129] In some embodiments, the poly(alkyloxazoline)-lipid conjugate (e.g., according to Formula I) comprises about 0.1 mol% to about 10 mol%, about 0.5 mol% to about 10 mol%, about 1 mol% to about 10 mol%, about 1.5 mol% to about 10 mol%, about 2 mol% to about 10 mol%, about 2.5 mol% to about 10 mol%, about 3 mol% to about 10 mol%, about 4 mol% to about 10 mol%, about 5 mol% to about 10 mol%, about 0.1 mol% to about 5 mol%, about 0.3 mol% to about 10 mol%, about 0.5 ...0.6 mol% to about 10 mol%, about 0.7 mol% to about 10 mol%, about 0.9 mol% to about 10 mol%, about 1.1 mol% to about 10 mol%, about 1.2 mol% to about 10 mol%, about 1.3 mol% to about 10 mol%, about 1.4 mol% to about 10 mol%, about 1.5 mol% to about 10 mol%, about 1. % to about 5 mol%, about 0.5 mol% to about 5 mol%, about 1 mol% to about 5 mol%, about 1.5 mol% to about 5 mol%, about 2 mol% to about 5 mol%, about 2.5 mol% to about 5 mol%, about 3 mol% to about 5 mol%, about 0.1 mol% to about 3 mol%, about 0.5 mol% to about 3 mol%, about 1 mol% to about 3 mol%, about 1.5 mol% to about 3 mol%, about 2 mol% to about 3 mol%, about 2.2 mol% to about 3 mol%, or about 2.5 mol% to about 3 mol%. In some embodiments, the poly(alkyloxazoline)-lipid conjugate (e.g., according to Formula I) present in the lipid particle accounts for about 0.1 mol%, about 0.5 mol%, about 1 mol%, about 1.2 mol%, about 1.4 mol%, about 1.5 mol%, about 1.6 mol%, about 1.8 mol%, about 2 mol%, about 2.2 mol%, about 2.5 mol%, or about 3 mol% of the total lipid present in the particle.

[0130] In certain embodiments, the lipid particles comprise: a cationic lipid that accounts for about 30 mol % to about 80 mol % of the total lipid present in the particle (e.g., about 40 mol % to about 70 mol %, about 45 mol % to about 65 mol %, about 45 mol % to about 60 mol %, or about 50 mol % to about 60 mol %) of the total lipid present in the particle; a neutral lipid, such as a phospholipid (e.g., about 3 mol % to about 20 mol %, about 5 mol % to about 15 mol %, or about 8 mol % to about 10 mol %) of the total lipid present in the particle; about 12 mol %); a sterol, such as cholesterol (e.g., about 10 mol % to about 60 mol %, about 20 mol % to about 50 mol %, or about 30 mol % to about 40 mol %) of the total lipid present in the particle; and a poly(alkyloxazoline)-lipid conjugate (e.g., according to Formula I) that accounts for about 0.1 mol % to about 10 mol % of the total lipid present in the particle (e.g., about 0.1 mol % to about 5 mol % or about 0.5 mol % to about 3 mol %) of the total lipid present in the particle.

[0131] In specific embodiments, the lipid particle comprises: a cationic lipid, which accounts for about 50 mol % to about 60 mol % of the total lipid present in the particle; a neutral lipid (e.g., a phospholipid), which accounts for about 8 mol % to about 12 mol % of the total lipid present in the particle; a sterol (e.g., cholesterol), which accounts for about 30 mol % to about 40 mol % of the total lipid present in the particle; and a poly(alkyloxazoline)-lipid conjugate (e.g., according to Formula I), which accounts for about 0.5 mol % to about 3 mol % of the total lipid present in the particle.

[0132] In an exemplary embodiment, the lipid particle comprises: a cationic lipid, the cationic lipid accounts for about 55mol% (e.g., 54.6mol%) of the total lipid present in the particle; a neutral lipid (e.g., phospholipid), the neutral lipid accounts for about 11mol% (e.g., 10.9mol%) of the total lipid present in the particle; a sterol (e.g., cholesterol), the sterol accounts for about 33mol% (e.g., 32.8mol%) of the total lipid present in the particle; and a poly (alkyl oxazoline) -lipid conjugate (e.g., according to Formula I), the poly (alkyl oxazoline) -lipid conjugate accounts for about 1.6mol% of the total lipid present in the particle. In some instances, the lipid particle is formulated into a pharmaceutical composition suitable for intravenous administration.

[0133] In another exemplary embodiment, the lipid particle comprises: a cationic lipid, the cationic lipid accounts for about 50.0mol% of the total lipid present in the particle; a neutral lipid (e.g., a phospholipid), the neutral lipid accounts for about 10mol% of the total lipid present in the particle; a sterol (e.g., cholesterol), the sterol accounts for about 38.5mol% of the total lipid present in the particle; and a poly (alkyl oxazoline) -lipid conjugate (e.g., according to Formula I), the poly (alkyl oxazoline) -lipid conjugate accounts for about 1.5mol% of the total lipid present in the particle. In certain instances, the lipid particle is formulated into a pharmaceutical composition suitable for intramuscular administration.

[0134] In yet another exemplary embodiment, the lipid particle comprises: a cationic lipid that accounts for approximately 50.5 mol % of the total lipid present in the particle; a neutral lipid (e.g., a phospholipid) that accounts for approximately 10 mol % (e.g., 10.1 mol %) of the total lipid present in the particle; a sterol (e.g., cholesterol) that accounts for approximately 39 mol % (e.g., 38.9 mol %) of the total lipid present in the particle; and a poly(alkyloxazoline)-lipid conjugate (e.g., according to Formula I) that accounts for approximately 0.5 mol % of the total lipid present in the particle.

[0135] In a further exemplary embodiment, the lipid particle comprises: a cationic lipid, which accounts for about 49 mol% (e.g., 49.2 mol%) of the total lipid present in the particle; a neutral lipid (e.g., a phospholipid), which accounts for about 10 mol% (e.g., 9.8 mol%) of the total lipid present in the particle; a sterol (e.g., cholesterol), which accounts for about 38 mol% (e.g., 37.9 mol%) of the total lipid present in the particle; and a poly(alkyloxazoline)-lipid conjugate (e.g., according to Formula I), which accounts for about 3.0 mol% of the total lipid present in the particle.

[0136] Any of a variety of cationic lipids can be used in the lipid particles described herein, alone or in combination with one or more other cationic lipid species or non-cationic lipid species.

[0137] Cationic lipids useful in the lipid particles described herein can be any of a number of lipid species that carry a net positive charge at physiological pH. Such lipids include, but are not limited to, N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleoyloxy-N,N-dimethylaminopropane (DODMA), 1,2-distearyloxy-N,N-dimethylaminopropane (DSDMA), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), 3-(N-(N',N'-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), N-(1,2-dimyristyl)- ...dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), 3-(N-(N',N'-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), N-(1,2-dimyristyl)-N,N-trimethylammonium chloride (DOTMA), N,N- Corioloyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE), 2,3-dioleoyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanium trifluoroacetate (DOSPA), dioctadecylamido glycylspermine (DOGS), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLenDMA), 3-dimethylamino-2-(cholest-5-ene-3-β-oxybutane-4-oxy)-1-(cis, cis-9,12-octadecadienyloxy)propane (CLinDMA), 2-[5'-(cholest-5-ene-3.β-oxy)-3'-oxapentyloxy)-3-dimethyl-1-(cis, cis-9',1-2'-octadecadienyloxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleoyloxybenzylamine (DMOBA), 1,2-N,N'-dioleylcarbamoyl-3-dimethylaminopropane (DOCarbDAP), 1,2-N,N'-dilinoleylcarbamoyl-3-dimethylaminopropane (DLincarbDAP), 1,2-dilinoleoylcarbamoyl-3-dimethylaminopropane (DLinCDAP), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)- [1,3]-dioxolane (DLin-K-C2-DMA), 2,2-dilinoleyl-4-(3-dimethylaminopropyl)-[1,3]-dioxolane (DLin-K-C3-DMA), 2,2-dilinoleyl-4-(4-dimethylaminobutyl)-[1,3]-dioxolane (DLin-K-C4-DMA), 2,2-dilinoleyl-5-dimethylaminomethyl-[1,3]-dioxane (DLin-K6-DMA), 2,2-dilinoleyl-4-N-methylpiperazinyl-[1,3]-dioxolane (DLin-K-MPZ), 2,2-dilinoleyl-4-dimethylamino methyl-[1,3]-dioxolane (DLin-K-DMA), 1,2-dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-dilinoleyloxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-dilinoleyloxy-3-morpholinopropane (DLin-MA), 1,2-dilinoleoyloxy-3-dimethylaminopropane (DLinDAP), 1,2-dilinoleoylthio-3-dimethylaminopropane (DLin-S-DMA), 1-linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2- DMAP), 1,2-dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-dilinoleyloxy-3-(N-methylpiperazinyl)propane (DLin-MPZ), 3-(N,N-dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-dioleylamino)-1,2-propanediol (DOAP), 1,2-dilinoleyloxy-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA) and mixtures thereof.

[0138] In certain embodiments, the cationic lipid is (6Z,16Z)-12-((Z)-dec-4-en-1-yl)docosa-6,16-dien-11-yl 5-(dimethylamino)pentanoate having the following structure:

[0139]

[0140] In certain other embodiments, the cationic lipid has the following structure:

[0141]

[0142] The non-cationic lipid used in the lipid particles described herein can be any of a variety of neutral uncharged, zwitterionic or anionic lipids.

[0143] Neutral lipids are an exemplary class of non-cationic lipids, which include phospholipids such as phosphatidylcholine, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine (LPE), phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetyl phosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyl-phosphatidylcholine (POPC), and the like. ), palmitoyl-phosphatidylethanolamine (POPE), palmitoyl-phosphatidylglycerol (POPG), dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), monomethyl-phosphatidylethanolamine, dimethyl-phosphatidylethanolamine, dilauroyl-phosphatidylethanolamine (DEPE), stearoyloleoyl-phosphatidylethanolamine (SOPE), lysophosphatidylcholine, dilinoleoylphosphatidylcholine and mixtures thereof. Other diacylphosphatidylcholine and diacylphosphatidylethanolamine phospholipids may also be used. The acyl groups in these lipids may be derived from C 10 -C 24 The acyl group of a carbon chain fatty acid, such as lauroyl, myristoyl, palmitoyl, stearoyl or oleoyl. In certain embodiments, the neutral lipid comprises DSPC.

[0144] Sterols are another exemplary class of non-cationic lipids, including cholesterol and its derivatives, such as cholestanol, cholestanone, cholestenone, coprosterol, cholesteryl-2'-hydroxyethyl ether, cholesteryl-4'-hydroxybutyl ether and mixtures thereof. In certain embodiments, the sterol includes cholesterol.

[0145] Any poly (alkyl oxazoline) -lipid conjugate according to formula I can be used in the lipid particles described herein. In an exemplary embodiment, the poly (alkyl oxazoline) portion of the conjugate includes a poly (2-ethyl 2-oxazoline) (PEOZ) polymer. In some embodiments, the poly (alkyl oxazoline) portion of the conjugate has an average molecular weight of about 2,000 Da to about 5,000 Da. In a specific embodiment, the poly (alkyl oxazoline) portion of the conjugate has an average molecular weight of about 5,000 Da. In some embodiments, the lipid portion of the conjugate comprises one or two independently selected C 12-18 In specific embodiments, the lipid portion of the conjugate comprises one or two independently selected C 12 , C 14 , C 16 or C 18 Alkyl Chains. Additional poly(alkyloxazoline)-lipid conjugates suitable for use in the lipid particles described herein include poly(alkyloxazoline)-dialkoxypropyl conjugates disclosed in U.S. Patent Publication No. 2011 / 0313017 and poly(alkyloxazoline)-phospholipid conjugates disclosed in International Publication No. WO 2010 / 006282.

[0146] V. Nucleic Acids

[0147] In certain embodiments, lipid granules described herein are associated with nucleic acids to produce nucleic acid-lipid granules. In some embodiments, nucleic acids are completely encapsulated in lipid granules. As used herein, the term "nucleic acid" includes any oligonucleotides or polynucleotides with a fragment containing up to 60 nucleotides and a longer fragment called polynucleotides commonly referred to as oligonucleotides. Nucleic acids can be used alone in lipid granules described herein, or with a lipid granule combination (e.g., co-administered) comprising a peptide, polypeptide or small molecule (e.g., conventional drug).

[0148] As used herein, the terms "polynucleotide" and "oligonucleotide" refer to polymers or oligomers of nucleotide monomers or nucleoside monomers composed of naturally occurring bases, sugars, and intersugar (backbone) bonds. The terms "polynucleotide" and "oligonucleotide" also include polymers or oligomers comprising non-naturally occurring monomers or functionally similar moieties. Such modified or substituted polynucleotides and oligonucleotides are often superior to the native form because of, for example, enhanced cellular uptake, reduced immunogenicity, and increased stability in the presence of nucleases.

[0149] Oligonucleotides are usually classified as deoxyribonucleotides or ribonucleotides. Deoxyribonucleotides are composed of a 5-carbon sugar called deoxyribose, which is covalently linked to a phosphate ester on the 5' and 3' carbons of the sugar to form an alternating, non-branched polymer. Ribonucleotides are composed of similar repeating structures, in which the 5-carbon sugar is ribose.

[0150] Nucleic acids present in lipid particles described herein include nucleic acids in any form known. Nucleic acids used herein can be single-stranded DNA or RNA (e.g., ssDNA or ssRNA), or double-stranded DNA or RNA (e.g., dsDNA or dsRNA), or DNA-RNA hybrids. Single-stranded nucleic acids include, for example, mRNA, guide RNA (gRNA), antisense oligonucleotides, ribozymes, mature miRNA and triple-stranded oligonucleotides (triplex-forming oligonucleotides). The example of double-stranded DNA includes, for example, structural genes, genes comprising control regions and termination regions, and self-replication systems (e.g., viruses or plasmid DNA). The example of double-stranded RNA includes, for example, siRNA and other RNAi agents (e.g., aiRNA and precursor miRNA).

[0151] Nucleic acid can have different lengths, usually depending on the concrete form of nucleic acid.For example, in specific embodiments, mRNA, plasmid or gene can be about 1,000 to about 100,000 nucleotides in length.In specific embodiments, oligonucleotide can be about 10 to about 100 nucleotides in length.In various related embodiments, the oligonucleotide of strand, double strand and triple strand can be about 10 to about 60 nucleotides, about 15 to about 60 nucleotides, about 20 to about 50 nucleotides, about 15 to about 30 nucleotides or about 20 to about 30 nucleotides in length.

[0152] In a specific embodiment, the oligonucleotide (or its chain) specifically hybridizes with the target polynucleotide sequence or is complementary to the target polynucleotide sequence. The terms "specific hybridization" and "complementation" used herein indicate a sufficient degree of complementarity so that stable and specific binding occurs between the DNA or RNA target and the oligonucleotide. It should be understood that the oligonucleotide does not need to be 100% complementary to the target nucleic acid sequence to be specifically hybridized with it. In some embodiments, when the combination of the oligonucleotide and the target sequence interferes with the normal function of the target sequence to cause the loss of its practicality or expression, the oligonucleotide is specifically hybridizable, and there is a sufficient degree of complementarity to avoid the non-specific binding of the oligonucleotide to the off-target sequence under the conditions of needing specific binding (that is, in the case of in vivo determination or treatment, under physiological conditions, or, in the case of in vitro determination, under the conditions of determination therein). Therefore, compared with the region of the gene or mRNA sequence targeted or specifically hybridized with it, the oligonucleotide can include 1, 2, 3 or more base substitutions.

[0153] A.mRNA

[0154] Certain embodiments provide compositions comprising lipid particles described herein and methods of using the compositions and methods thereof for expressing one or more mRNA molecules (e.g., a mixture of mRNA molecules (cocktail)) in cells (e.g., cells in the human body). mRNA molecules encode one or more polypeptides expressed in cells. Lipid particle preparations comprising mRNA molecules described herein can be used for a variety of applications, including protein replacement therapy, vaccines, cancer immunotherapy, and gene editing. In some embodiments, lipid particles described herein are used to treat diseases, wherein the expression of polypeptides encoded by mRNA molecules in diseased organisms (e.g., mammals, such as humans) improves one or more symptoms of the disease. The compositions and methods described herein are particularly useful for treating human diseases caused by a lack of functional polypeptides in the human body or a reduction in levels. In other embodiments, lipid particles described herein are used as vaccines for preventing diseases, wherein the expression of polypeptides encoded by mRNA molecules in organisms (e.g., mammals, such as humans) causes immunity against diseases. The compositions and methods described herein are particularly useful for stimulating the adaptive immune system to produce antibodies against pathogens by expressing antigenic polypeptides (e.g., from mRNA molecules encoding viral proteins such as S (spike), E (capsule), M (membrane) or N (nucleocapsid) proteins or antigenic fragments thereof) to produce an immune response in an organism (e.g., a mammal, such as a human) to prevent infectious diseases caused by pathogens, for example, viruses (e.g., coronaviruses such as SARS-CoV-2). In other embodiments, the lipid particles described herein are used as vaccines for treating diseases, wherein the expression of polypeptides encoded by mRNA molecules in an organism (e.g., a mammal, such as a human) causes an immune response against diseased cells. The compositions and methods described herein are particularly useful for stimulating an adaptive immune response to produce antibodies that target cancer cells and destroy cancer cells by expressing antigenic polypeptides (e.g., from mRNA molecules encoding tumor-specific antigens or antigenic fragments thereof) to treat cancer.

[0155] In some embodiments, mRNA molecules are completely encapsulated in lipid particles.About the preparation comprising mRNA mixture, different types of mRNA species present in the mixture (for example, mRNA with different sequences) can be co-encapsulated in the same particle, or each type of mRNA species present in the mixture can be encapsulated in a separate particle. The mRNA mixture can be formulated in the particle described herein using a mixture of two or more independent mRNAs (each with a unique sequence) of the same, similar or different concentrations or mol ratios. In one embodiment, a mixture of mRNA (corresponding to multiple mRNAs with different sequences) is prepared using the same, similar or different concentrations or mol ratios of each mRNA species, and different types of mRNA are co-encapsulated in the same particle. In another embodiment, each type of mRNA species present in the mixture is encapsulated in different particles with the same, similar or different mRNA concentrations or mol ratios, and the particles thus formed (each containing different mRNA payloads) are separated (for example, at different times according to prevention or treatment regimens), or combined as a single unit dose and administered together (for example, administered together with a pharmaceutically acceptable carrier). In specific embodiments, the lipid particles are serum stable, resistant to nuclease degradation, and substantially non-toxic to mammals, such as humans.

[0156] 1. Modification of mRNA

[0157] The mRNA molecule present in the lipid particle can contain one, two or more than two nucleoside modifications. In some embodiments, the modified mRNA exhibits reduced degradation in a cell into which the mRNA has been introduced relative to the corresponding unmodified mRNA.

[0158] In some embodiments, modified nucleosides include pyridin-4-one ribonucleosides, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurine methyl uridine, 1-taurine methyl-pseudouridine, 5-taurine methyl-2-thio-uridine, 1-taurine methyl uridine, 2-thio-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine and 4-methoxy-2-thio-pseudouridine.

[0159] In some embodiments, modified nucleosides include 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolocytidine, pyrrolopseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, Cytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebulline, 5-aza-zebulline, 5-methyl-zebulline, 5-aza-2-thio-bamboephedrine, 2-thio-zebulline, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine and 4-methoxy-1-methyl-pseudoisocytidine.

[0160] In other embodiments, the modified nucleosides include 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyl adenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycylaminoformyladenosine, N6-threonylaminoformyladenosine, 2-methylthio-N6-threonylaminoformyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine and 2-methoxy-adenine.

[0161] In certain embodiments, the modified nucleoside is 5'-O-(1-phosphorothioate)-adenosine, 5'-O-(1-phosphorothioate)-cytidine, 5'-O-(1-phosphorothioate)-guanosine, 5'-O-(1-phosphorothioate)-uridine or 5'-O-(1-phosphorothioate)-pseudouridine. The phosphate moiety of α-thio substitution is provided to confer RNA polymer stability through the non-natural phosphorothioate backbone connection. Phosphorothioate RNA has increased nuclease resistance and subsequently has a longer half-life in the cellular environment. It is expected that the nucleic acid connected by phosphorothioate also reduces the innate immune response by the weaker binding / activation of the cell innate immune molecules.

[0162] In certain embodiments, for example, if precise timing of protein production is desired, intracellular degradation of a modified nucleic acid introduced into a cell is desired. Accordingly, the present disclosure provides modified nucleic acids containing a degradation domain that are capable of functioning in a directed manner within a cell.

[0163] In other embodiments, modified nucleosides include inosine, 1-methyl-inosine, wyosine, wyobutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine and N2,N2-dimethyl-6-thio-guanosine.

[0164] 2. Optional mRNA components

[0165] In a further embodiment, the mRNA molecule present in the lipid granule may include other optional components. These optional components include but are not limited to untranslated regions, Kozak sequences, intronic nucleotide sequences, internal ribosome entry sites (IRES), caps and poly-A tails. For example, 5' untranslated regions (UTRs) and / or 3'UTRs may be included, one or both of which may independently contain one or more different nucleoside modifications. In this embodiment, nucleoside modifications may also be present in the translatable region. An mRNA molecule containing a Kozak sequence is also provided. In addition, an mRNA molecule containing one or more intronic nucleotide sequences that can be cut from an mRNA sequence is provided herein.

[0166] a. Untranslated region (UTR)

[0167] The untranslated region (UTR) of a gene is transcribed but not translated. The 5'UTR starts at the transcription start site and continues to the start codon, but does not include the start codon; however, the 3'UTR starts immediately after the stop codon and continues until the transcription termination signal. There is increasing evidence for the regulatory role played by UTR in the stability and translation of mRNA molecules. The regulatory features of UTR can be incorporated into the mRNA used for the lipid particles described herein to increase the stability of the molecule. Specific features can also be combined to ensure the controlled downregulation of transcripts in the case where transcripts are mistakenly directed to undesirable tissues or organ sites.

[0168] b.5' cap

[0169] The 5' cap structure of mRNA is involved in nuclear export, increases mRNA stability, and binds mRNA cap binding protein (CBP), which is responsible for mRNA stability and translation competence in cells through the association of CBP with poly(A) binding protein to form mature circular mRNA species. The cap also helps to remove 5' proximal introns during mRNA splicing.

[0170] Endogenous mRNA molecules can be 5'-capped, thereby generating a 5'-PPP-5'-triphosphate connection between the terminal guanosine cap residue of the mRNA molecule and the 5'-terminal transcribed sense nucleotide. The 5'-guanylate cap can then be methylated to produce an N7-methyl-guanylate residue. The ribose sugar of the nucleotides transcribed at the end and / or the reverse end of the 5' end of the mRNA can also be optionally 2'-O-methylated. The 5'-decapping by hydrolysis and cleavage of the guanylate cap structure can target the mRNA molecule for degradation.

[0171] c.IRES sequence

[0172] mRNA containing an internal ribosome entry site (IRES) can also be used in lipid particles described herein. IRES can be used as a unique ribosome binding site, or can be used as one of multiple ribosome binding sites of mRNA. mRNA containing more than one functional ribosome binding site can encode several peptides or polypeptides independently translated by ribosomes ("polycistronic mRNA"). When mRNA has an IRES, a second translatable region is further optionally provided. Examples of IRES sequences include, but are not limited to, from small RNA viruses (e.g., FMDV), harmful viruses (e.g., CFFV), poliovirus (PV), encephalomyocarditis virus (ECMV), foot-and-mouth disease virus (FMDV), hepatitis C virus (HCV), swine fever virus (CSFV), murine leukemia virus (MLV), simian immunodeficiency virus (S1V) and cricket paralysis virus (CrPV).

[0173] d. Poly-A tail

[0174] During RNA processing, long chains of adenine nucleotides (poly-A tails) can be added to polynucleotides such as mRNA molecules to improve stability. The 3' end of the transcript can be cleaved immediately after transcription to free the 3' hydroxyl. Then, poly-A polymerase adds the adenine nucleotide chain to the RNA. This method is called polyadenylation, and a poly-A tail that can be 100 to 250 residues long is added.

[0175] Typically, the length of the poly-A tail is greater than 30 nucleotides in length. In some embodiments, the poly-A tail is greater than 35 nucleotides in length (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2,000, 2,500, and 3,000 nucleotides). In some embodiments, the poly-A tail can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% larger than the mRNA in length. In other embodiments, the poly-A tail can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the total length of the mRNA.

[0176] 3. Produce mRNA molecules

[0177] Methods for isolating RNA, synthesizing RNA, hybridizing nucleic acids, preparing and screening cDNA libraries, and performing PCR are well known in the art (see, e.g., Gubler and Hoffman, Gene, 25:263-269 (1983); Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed. 1989)), as well as PCR methods (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds., 1990)). Expression libraries are also well known to those skilled in the art. Additional basic texts that disclose general methods for use in the present disclosure include Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994).

[0178] 4. Application of mRNA therapy

[0179] The mRNA component of lipid granule described herein can be used to express target polypeptide.Some diseases of people are caused by the disappearance or damage of functional protein in the cell type that albumen normally exists and is active.Functional protein can lack completely or in part, and this is because for example, the transcription of coding gene is inactive or because there is sudden change that makes albumen completely or in part non-functional in coding gene. Examples of human diseases caused by complete or partial inactivation of proteins include methylmalonic acidemia (caused by a defect in methylmalonyl-CoA mutase), glycogen storage disease type 1A (caused by a defect in the catalytic subunit of glucose-6-phosphatase), glycogen storage disease type 1B (caused by a deficiency in glucose-6-phosphate translocase), fragile X syndrome (caused by a defect in the FMR1 protein), urea cycle disorders (caused by mutations in the ornithine transcarbamyltransferase (OTC) gene), Creutzfeldt-Nathan syndrome type 1 (caused by inherited mutations resulting in a deficiency in bilirubin uridine diphosphate glucuronosyltransferase (bilirubin-UGT)), alpha-1 antitrypsin deficiency (caused by mutations in the SERPINA1 gene), thrombotic thrombocytopenic purpura (caused by mutations in the disintegrin and metalloproteinase with thrombospondin type 1 motif member 13 (ADAMTS13) gene), acute intermittent porphyria (caused by inherited mutations at the PBGD locus), factor IX deficiency hemophilia B (caused by a defect in the factor IX (FIX) protein), X-linked severe combined immunodeficiency (X-SCID) (caused by one or more mutations in the gene encoding the common gamma chain protein, which is a component of the receptors for several interleukins involved in the development and maturation of B and T cells within the immune system), and X-linked adrenoleukodystrophy (X-ALD) (caused by one or more mutations in the gene for a peroxisomal membrane transporter called ABCD1).

[0180] In some embodiments, the mRNA components of lipid granules described herein express infectious disease antigens, such as viruses, bacteria, fungi, protozoa and / or worm infectious disease antigens.This vaccine comprising the lipid granules of the mRNA with encoded antigens can be particularly used for preventing or treating infectious diseases.In certain embodiments, infectious disease antigens are from coronavirus (for example, SARS-CoV-1, SARS-CoV-2, MERS-CoV), influenza virus (for example, influenza A, B and C virus), filovirus (for example, Ebola virus, Marburg virus), arenavirus (for example, Lassa virus, Junin (Junin) virus, Machupo (Machupo) virus, Guanarito (Guanarito) virus, Sabia (Sabia) virus), Zika virus, rabies virus, rhinovirus, simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), hepatitis virus (for example, hepatitis C virus), herpes simplex virus, human papillomavirus (HPV) or Epstein-Barr virus viral infectious disease antigens. In a specific embodiment, the infectious disease antigen is a SARS-CoV 2 protein selected from the group consisting of S (spike) protein, E (envelope) protein, M (membrane) protein, N (nucleocapsid) protein, and antigenic fragments thereof. In certain instances, the development of antigen-specific immunity from mRNA vaccines requires transfection of antigen-presenting cells, such as dendritic cells. Administration is typically accomplished by intradermal, intramuscular, or subcutaneous injection, as dendritic cells densely populate skin tissue and skeletal muscle.

[0181] In some embodiments, the mRNA components of lipid particles described herein express tumor-associated antigens. In some examples, after mRNA cancer vaccines are administered to dendritic cells, cytotoxic T cells can target and destroy tumors. In other embodiments, the mRNA components of lipid particles described herein express chimeric antigen receptors (CARs) for CAR T cell therapy. Typically, the T cells of the subject are separated and transfected in vitro with mRNA encoding CAR, which is a protein fragment displayed on the surface of T cells and binds to specific tumor epitopes. After the modified T cells are reintroduced into the subject, CAR targets tumor cells and kills tumor cells.

[0182] In some embodiments, the mRNA component of the lipid particles described herein expresses gene editing nuclease. Examples of gene editing nucleases include CRISPR / Cas nucleases (e.g., Cas9, Cpf1), zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and mega nucleases. CRISPR-mediated gene editing requires Cas nucleases responsible for DNA cleavage and short guide RNAs (gRNAs) that instruct Cas nucleases to cleave DNA at precise locations. In some embodiments, gRNA targets Cas nucleases to genes in viral genomes. As a non-limiting example, the viral genome is a SARS-CoV-2 genome, and the gene is selected from orf1ab, S gene, ORF3a, E gene, M gene, ORF6, ORF7a, ORF8, N gene, and ORF10. In some examples, mRNA and gRNA encoding Cas nucleases such as Cas9 are encapsulated in the same lipid particles. In other examples, mRNA and gRNA encoding Cas nucleases are encapsulated in separate lipid particles.

[0183] B.siRNA

[0184] The siRNA component of the lipid particles described herein can silence the expression of the target gene. Generally, each chain of the siRNA duplex is about 15 to about 60 nucleotides in length, preferably about 15 to about 30 nucleotides in length. In certain embodiments, the siRNA comprises at least one modified nucleotide. Generally, the modified siRNA has less immunostimulation than the corresponding unmodified siRNA sequence and retains RNAi activity for the target gene of interest. In some embodiments, the modified siRNA contains at least one 2'OMe-purine or pyrimidine nucleotide, such as 2'OMe-guanosine, 2'OMe-uridine, 2'OMe-adenosine and / or 2'OMe-cytosine nucleotide. The modified nucleotides can be present in one chain (i.e., sense or antisense) or two chains of the siRNA. The siRNA sequence can have an overhang (e.g., as Elbashir et al., Genes Dev., 15:188 (2001) or et al., Cell, 107:309 (2001)), or may lack overhangs (ie, have blunt ends).

[0185] Suitable siRNA sequences can be identified using any method known in the art. Typically, the methods described in Elbashir et al., Nature, 411:494-498 (2001) and Elbashir et al., EMBO J., 20:6877-6888 (2001) are combined with the rational design rules described in Reynolds et al., Nature Biotech., 22 (3):326-330 (2004).

[0186] siRNA can be provided in several forms, including, for example, as one or more isolated small interfering RNA (siRNA) duplexes, as longer double-stranded RNA (dsRNA), or as siRNA or dsRNA transcribed from a transcription cassette in a DNA plasmid. siRNA can be chemically synthesized. Oligonucleotides comprising siRNA molecules can be synthesized using any of a variety of techniques known in the art, such as those described by Usman et al., J. Am. Chem. Soc., 109: 7845 (1987); Scaringe et al., Nucl. Acids Res., 18: 5433 (1990); Wincott et al., Nucl. Acids Res., 23: 2677-2684 (1995); and Wincot et al., Methods Mol. Bio., 74: 59 (1997).

[0187] Examples of modified nucleotides include, but are not limited to, ribonucleotides with 2'-O-methyl (2'OMe), 2'-deoxy-2'-fluoro (2'F), 2'-deoxy, 5-C-methyl, 2'-O-(2-methoxyethyl) (MOE), 4'-thio, 2'-amino or 2'-C-allyl groups. Modified nucleotides with Northern conformation, such as those described in, for example, Saenger, Principles of Nucleic Acid Structure, Springer-Verlag Ed. (1984), are also suitable for use in siRNA molecules. Such modified nucleotides include, but are not limited to, locked nucleic acid (LNA) nucleotides (e.g., 2'-0,4'-C-methylene-(D-ribofuranosyl) nucleotides), 2'-0-(2-methoxyethyl) (MOE) nucleotides, 2'-methyl-thio-ethyl nucleotides, 2'-deoxy-2'-fluoro (2'F) nucleotides, 2'-deoxy-2'-chloro (2'Cl) nucleotides, and 2'-azido nucleotides. In certain examples, the siRNA molecules described herein include one or more G-clamp nucleotides. G-clamp nucleotides refer to modified cytosine analogs, wherein the modification confers the ability to hydrogen bond to both the Watson-Crick and Hoogsteen faces of complementary guanine nucleotides within the duplex (see, e.g., Lin et al., J. Am. Chem. Soc., 120: 8531-8532 (1998)). In addition, nucleotides having nucleotide base analogs, e.g., C-phenyl, C-naphthyl, other aromatic derivatives, inosine, pyrrolecarboxamides, and nitroazole derivatives (e.g., 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole) (see, e.g., Loakes, Nucl. Acids Res., 29:2437-2447 (2001)) can be incorporated into siRNA molecules.

[0188] In certain embodiments, the siRNA molecule may further comprise one or more chemical modifications, such as a terminal cap moiety, a phosphate backbone modification, etc. Examples of terminal cap moieties include, but are not limited to, inverted deoxy abasic residues, glyceryl modifications, 4',5'-methylene nucleotides, 1-(β-D-furanerythrosyl) nucleotides, 4'-thionucleotides, carbocyclic nucleotides, 1,5-anhydrohexitol nucleotides, L-nucleotides, α-nucleotides, modified base nucleotides, threo-pentofuranosyl nucleotides, acyclic 3',4'-secondary nucleotides, acyclic 3,4-dihydroxybutyl nucleotides, acyclic 3,5-dihydroxypentyl nucleotides, 3'-3'-inverted nucleotide moieties, 3'-3'-inverted abasic moieties, 3'-2'-inverted nucleotide moieties, 3'-2'-inverted abasic moieties, 5'-5'-inverted nucleotide ... '-reverse abasic moiety, 3'-5'-inverted deoxy abasic moiety, 5'-amino-alkyl phosphate, 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate, 6-aminohexyl phosphate, 1,2-aminododecyl phosphate, hydroxypropyl phosphate, 1,4-butanediol phosphate, 3'-phosphoramidate, 5'-phosphoramidate, hexyl phosphate, aminohexyl phosphate, 3'-phosphate, 5'-amino, 3'-phosphorothioate, 5'-phosphorothioate, phosphorodithioate and bridged or non-bridged methylphosphonate or 5'-thiol moiety (see, e.g., U.S. Pat. No. 5,998,203; Beaucage et al., Tetrahedron 49:1925 (1993)). Non-limiting examples of phosphate backbone modifications (i.e., generating modified internucleotide linkages) include phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amidate, carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, methylal, thiomethylal, and alkylsilyl substitutions (see, e.g., Hunziker et al. Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods, VCH, 331-417 (1995); Mesmaeker et al., Novel Backbone Replacements for Oligonucleotides, in Carbohydrate Modifications in Antisense Research, ACS, 24-39 (1994)). Such chemical modifications can occur at the 5'-end and / or 3'-end of the sense strand, the antisense strand, or both strands of the siRNA.

[0189] In some embodiments, the sense strand and / or antisense strand of the siRNA molecule may also include a 3'-terminal overhang having about 1 to about 4 (e.g., 1, 2, 3, or 4) 2'-deoxyribonucleotides and / or any combination of modified and unmodified nucleotides. Other examples of modified nucleotides and chemical modification types that can be introduced into siRNA molecules are described in, for example, UK Patent No. GB2,397,818B and U.S. Patent Publication Nos. 20040192626, 20050282188, and 20070135372.

[0190] The siRNA molecules described herein may optionally include one or more non-nucleotides in one or both strands of the siRNA. As used herein, the term "non-nucleotide" refers to any group or compound that can be incorporated into a nucleic acid chain to replace one or more nucleotide units (including sugar and / or phosphate substitutions) and allow the remaining bases to exhibit their activity. The group or compound is abasic because it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine, and therefore lacks a base at the 1'-position.

[0191] In other embodiments, the chemical modification of siRNA includes connecting a conjugate to the siRNA molecule. The conjugate can be connected to the 5' and / or 3'-end of the sense strand and / or antisense strand of the siRNA via covalent bonding (e.g., biodegradable linker). The conjugate can also be connected to the siRNA (see, e.g., U.S. Patent Publication Nos. 20050074771, 20050043219, and 20050158727), for example, via a carbamate group or other linking group. In some examples, the conjugate is a molecule that helps siRNA to be delivered to the cell. Examples of conjugate molecules suitable for attachment to siRNA include, but are not limited to, steroids (e.g., cholesterol), glycols (e.g., polyethylene glycol (PEG)), human serum albumin (HSA), fatty acids, carotenoids, terpenes, bile acids, folates (e.g., folic acid, folate analogs and derivatives thereof), sugars (e.g., galactose, galactosamine, N-acetylgalactosamine, glucose, mannose, fructose, fucose, etc.), phospholipids, peptides, ligands of cellular receptors capable of mediating cellular uptake, and combinations thereof (see, e.g., U.S. Patent Publication Nos. 20030130186, 20040110296, and 20040249178; U.S. Patent No. 6,753,423). Other examples include lipophilic moieties, vitamins, polymers, peptides, proteins, nucleic acids, small molecules, oligosaccharides, carbohydrate clusters, intercalators, minor groove binders, cleavage agents and cross-linking agent conjugate molecules described in U.S. Patent Publication No. 20050119470 and 20050107325. Still other examples include 2'-O-alkylamines, 2'-O-alkoxyalkylamines, polyamines, C5-cationic modified pyrimidines, cationic peptides, guanidine groups, amidinium groups, cationic amino acid conjugate molecules described in U.S. Patent Publication No. 20050153337. Additional examples include hydrophobic groups, membrane active compounds, cell penetrating compounds, cell targeting signals, interaction regulators and steric stabilizer conjugate molecules described in U.S. Patent Publication No. 20040167090. Other examples include conjugate molecules described in U.S. Patent Publication No. 20050239739. The type of conjugate used and the degree of conjugation to the siRNA molecule can evaluate the improved pharmacokinetic characteristics, bioavailability and / or stability of the siRNA while maintaining RNAi activity. Therefore, those skilled in the art can use any of the various well-known in vitro cell culture or in vivo animal models to screen the siRNA molecules with various conjugates connected thereto to identify siRNA molecules with improved properties and full RNAi activity.

[0192] The siRNA components of lipid particles described herein can be used to down-regulate or silence the translation (i.e., expression) of target genes. Interested genes include, but are not limited to, genes related to viral infection and survival, genes related to metabolic diseases and illness (e.g., liver disease and illness), genes related to tumorigenesis and cell transformation (e.g., cancer), angiogenesis genes, immunomodulator genes (e.g., genes related to inflammation and autoimmune response), ligand receptor genes, and genes related to neurodegenerative disorders.

[0193] In order to combine, enter and replicate in cells, genes related to viral infection and survival include those expressed by viruses. Particularly interested viral sequences include sequences from coronaviruses (e.g., SARS-CoV-1, SARS-CoV-2, MERS-CoV), influenza viruses (e.g., influenza A, B and C viruses), filoviruses (e.g., Ebola, Marburg), arenaviruses (e.g., Lassa, Junin, Machupo, Guanarito, Sabia), Zika, rabies, rhinoviruses, simian immunodeficiency viruses (SIV), human immunodeficiency viruses (HIV), hepatitis viruses (e.g., hepatitis C), herpes simplex viruses, human papillomaviruses (HPV) or Epstein-Barr viruses. Exemplary coronaviruses (e.g., SARS-CoV-2) nucleic acid sequences that can be silenced include, but are not limited to, nucleic acid sequences encoding S (spike) proteins, E (envelope) proteins, M (membrane) proteins and N (nucleocapsid) proteins. Exemplary filovirus nucleic acid sequences that can be silenced include, but are not limited to, nucleic acid sequences encoding structural proteins (e.g., VP30, VP35, nucleoprotein (NP), polymerase protein (L-pol)) and membrane-associated proteins (e.g., VP40, glycoprotein (GP), VP24). Exemplary influenza virus nucleic acid sequences that can be silenced include, but are not limited to, nucleic acid sequences encoding nucleoprotein (NP), matrix proteins (M1 and M2), non-structural proteins (NS1 and NS2), RNA polymerase (PA, PB1, PB2), neuraminidase (NA) and hemagglutinin (HA). Exemplary hepatitis virus nucleic acid sequences that can be silenced include, but are not limited to, nucleic acid sequences involved in transcription and translation (e.g., En1, En2, X, P) and nucleic acid sequences encoding structural proteins (e.g., nucleoprotein (including C and C-related proteins), capsid and envelope proteins (including S, M and / or L proteins), or fragments thereof).

[0194] Genes associated with metabolic diseases and disorders (e.g., disorders in which the liver is a target and liver diseases and disorders) include, for example, genes expressed in dyslipidemia (e.g., liver X receptors (such as LXR and LXR), farnesoid X receptor (FXR), sterol regulatory element binding protein (SREBP), site-1 protease (S1P), 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMG coenzyme-A reductase), apolipoprotein B (ApoB), apolipoprotein CIII (ApoC3) and apolipoprotein E (ApoE); and diabetes (e.g., glucose 6-phosphatase). It will be appreciated by those skilled in the art that genes associated with metabolic diseases and disorders (e.g., diseases and disorders in which the liver is a target and liver diseases and disorders) include genes expressed in the liver itself as well as genes expressed in other organs and tissues. Silencing of sequences encoding genes associated with metabolic diseases and disorders can be conveniently used in combination with the administration of conventional agents for treating the disease or disorder.

[0195] Examples of gene sequences associated with tumorigenesis and cellular transformation (e.g., cancer or other neoplasia) include mitotic kines such as EG5 (KSP, KIF11); serine / threonine kinases such as polo-like kinase 1 (PLK-1); tyrosine kinases such as WEE1; apoptosis inhibitors such as XIAP; COP9 signal transducer subunits such as CSN1, CSN2, CSN3, CSN4, CSN5, CSN6, CSN7A, CSN7B, and CSN8; ubiquitin ligases such as COP1 (RFWD2); and histone deacetylases such as HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, etc.

[0196] Other examples of gene sequences associated with tumorigenesis and cellular transformation include translocation sequences, such as MLL fusion genes, BCR-ABL, TEL-AML1, EWS-FLI1, TLS-FUS, PAX3-FKHR, BCL-2, AML1-ETO, and AML1-MTG8; overexpressed sequences, such as multidrug resistance genes, cell cycle proteins, β-catenin, telomerase genes, c-MYC, N-MYC, BCL-2, growth factor receptors (e.g., EGFR / ErbBl, ErbB2 / HER-2, ErbB3, and ErbB4); and mutated sequences, such as RAS.

[0197] Silencing of sequences encoding DNA repair enzymes can be used in combination with chemotherapeutic agents. Genes encoding proteins associated with tumor migration are also target sequences of interest, for example, integrins, selectins, and metalloproteinases. The above examples are not exclusive. It will be appreciated by those skilled in the art that any complete or partial gene sequence that contributes to or promotes tumorigenesis or cell transformation, tumor growth, or tumor migration can be included as a template sequence.

[0198] Angiogenic genes can promote the formation of new blood vessels. Specific targets are vascular endothelial growth factor (VEGF) or VEGFR. Anti-angiogenic genes can inhibit the formation of new blood vessels. These genes can be used in particular to treat those cancers in which angiogenesis plays a role in the pathological development of the disease. Examples of anti-angiogenic genes include, but are not limited to, endostatin, angiostatin and VEGFR2.

[0199] Immunomodulator gene is a gene that regulates one or more immune responses. Examples of immunomodulator genes include, but are not limited to, cytokines, such as growth factors (e.g., TGF-α, TGF-β, EGF, FGF, IGF, NGF, PDGF, CGF, GM-CSF, SCF, etc.), interleukins (e.g., IL-2, IL-4, IL-12, IL-15, IL-18, IL-20, etc.), interferons (e.g., IFN-α, IFN-β, IFN-γ, etc.) and TNF. Fas and Fas ligand genes are also target immunomodulatory target sequences. Genes encoding secondary signaling molecules in hematopoiesis and lymphocytes are also included, such as Tec family kinases such as Bruton's tyrosine kinase (Btk).

[0200] Cell receptor ligands include ligands that can bind to cell surface receptors (e.g., insulin receptors, EPO receptors, G-protein coupled receptors, receptors with tyrosine kinase activity, cytokine receptors, growth factor receptors, etc.) to modulate (e.g., inhibit, activate, etc.) physiological pathways involving receptors (e.g., glucose level regulation, blood cell development, mitogenic effects, etc.). Examples of cell receptor ligands include, but are not limited to, cytokines, growth factors, interleukins, interferons, erythropoietin (EPO), insulin, glucagon, G-protein coupled receptor ligands, etc. Templates encoding for trinucleotide repeat (e.g., CAG repeat) expansion can be used to silence pathogenic sequences in neurodegenerative disorders caused by trinucleotide repeat expansion, such as spinobulbular muscular atrophy and Huntington's disease.

[0201] Certain other target genes that can be targeted by nucleic acids (e.g., siRNA) to downregulate or silence gene expression include, but are not limited to, actin, alpha 2, smooth muscle, aorta (ACTA2), alcohol dehydrogenase 1A (ADH1A, alcohol dehydrogenase 4 (ADH4), alcohol dehydrogenase 6 (ADH6), Afamin (AFM), angiotensinogen (AGT), serine-pyruvate aminotransferase (AGXT), alpha-2-HS-glycoprotein (AHSG), bacterial ketoaldehyde reductase family 1 member C4 (AKR1C4), serum albumin (ALB), alpha-1-microglobulin / bikunitz inhibitor (bikunin) precursor (AMBP), angiopoietin-related protein 3 (ANGPTL3) , serum amyloid P-component (APCS), apolipoprotein A-II (ApoA2), apolipoprotein B-100 (APOB), apolipoprotein C3 (APOC3), apolipoprotein C-IV (APOC4), apolipoprotein F (APOF), beta-2-glycoprotein 1 (ApoH), aquaporin-9 (AQP9), bile acid-CoA:amino acid N-acyltransferase (BAAT), C4b-binding protein beta chain (C4BPB), putative uncharacterized protein encoded by LINC01554 (C5orf27), complement factor 3 (C3), complement factor 5 (C5), complement component C6 (C6), complement component C8 alpha chain (C8A), complement component C8 beta chain (C8b), complement component C8γ chain (C8G), complement component C9 (C9), calmodulin-binding transcription activator 1 (CAMTA1), CD38 (CD38), complement factor B (CFB), complement factor H-related protein 1 (CFHR1), complement factor H-related protein 2 (CFHR2), complement factor H-related protein 3 (CFHR3), cannabinoid receptor 1 (CNR1), ceruloplasmin (CP), carboxypeptidase B2 (CPB2), connective tissue growth factor (CTGF), CXC motif chemokine 2 (CXCL2), cytochrome P4501A2 (CYP1A2), cytochrome P4502A6 (CYP2A6), cytochrome P4502C8 ( CYP2C8), cytochrome P4502C9 (CYP2C9), cytochrome P450 family 2 subfamily D member 6 (CYP2D6), cytochrome P4502E1 (CYP2E1), phylloquinone ω-hydroxylase CYP4F2 (CYP4F2), 7-α-hydroxycholest-4-en-3-one 12-α-hydroxylase (CYP8B1), dipeptidyl peptidase 4 (DPP4), coagulation factor 12 (F12), coagulation factor II (thrombin) (F2), coagulation factor LX (F9), fibrinogen α chain (FGA), fibrinogen β chain (FGB), fibrinogen γ chain (FGG), fibrinogen-like 1 (FGL1), monooxygenase 3 (FM03),Contains monooxygenase 5 (FM05), group-specific component (vitamin D binding protein) (GC), growth hormone receptor (GHR), glycine N-methyltransferase (GNMT), hyaluronan binding protein 2 (HABP2), escin antimicrobial peptide (HAMP), hydroxy acid oxidase (glycolate oxidase) 1 (Haol), HGF activator (HGFAC), haptoglobin-related protein; haptoglobin (HPR), heme-binding protein (HPX), histidine-rich glycoprotein (HRG), hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), hydroxysteroid (17-beta) dehydrogenase 13 (HSD17B13), alpha-endotrypsin inhibitor heavy chain H1 (ITIH1), alpha-endotrypsin inhibitor heavy chain H2 (ITIH2), alpha-endotrypsin inhibitor heavy chain H3 (ITIH3), α-endotrypsin inhibitor heavy chain H4 (ITIH4), kallikrein (KLKB1), lactate dehydrogenase A (LDHA), liver expressed antimicrobial peptide 2 (LEAP2), leukocyte-derived chemotactic protein 2 (LECT2), lipoprotein (a) (LPA), mannan-binding lectin serine peptidase 2 (MASP2), S-adenosylmethionine synthase isoform 1 (MAT1A), NADPH oxidase 4 (NOX4), poly [ADP-ribose] polymerase 1 (PARP1), paraoxonase 1 (PON1), paraoxonase 3 (PON3), vitamin K-dependent protein C (PROC), retinol dehydrogenase 16 (RDH16), serum amyloid A4, constitutive (SAA4), serine dehydratase (SDS), serpin family A member 1 (SERPINA1), serpin A11 (SERPINA11), carlistatin (SERPINA4), corticosteroid binding globulin (SERPINA6), antithrombin-PI (SERPINC1), heparin cofactor 2 (SERPIND1), Serpin family H member 1 (SERPINH1), solute carrier family 5 member 2 (SLC5A2), sodium / bile acid cotransporter (SLC10A1), solute carrier family 13 member 5 (SLC13A5), solute carrier family 22 member 1 (SLC22A1), solute carrier family 25 member 47 (SLC25 A47), solute carrier family 2, facilitating glucose transporter member 2 (SLC2A2), sodium-coupled neutral amino acid transporter 4 (SLC38A4), solute carrier organic anion transporter family member 1B1 (SLCO1B1), sphingomyelin phosphodiesterase 1 (SMPD1), bile salt sulfotransferase (SEILT2A1), tyrosine aminotransferase (TAT), tryptophan 2,3-dioxygenase (TDO2), UDP glucuronosyltransferase 2 family,Polypeptide B10 (UGT2B10), UDP glucuronyltransferase 2 family, Polypeptide B15 (UGT2B15), UDP glucuronyltransferase 2 family, Polypeptide B4 (UGT2B4) and vitronectin (VTN).

[0202] C.aiRNA

[0203] Like siRNA, asymmetric interfering RNA (aiRNA) can recruit RNA-induced silencing complex (RISC) and lead to effective silencing of various genes in mammalian cells by mediating sequence-specific cleavage of target sequence between nucleotide 10 and nucleotide 11 relative to the 5' end of antisense strand (Sun et al., Nat. Biotech., 26: 1379-1382 (2008)). Generally, aiRNA molecules include short RNA duplexes with sense strand and antisense strand, wherein the duplexes contain overhangs at the 3' end and 5' end of the antisense strand. AiRNA is generally asymmetric because the sense strand is shorter at both ends when compared with the complementary antisense strand. In some aspects, aiRNA molecules can be designed, synthesized and annealed under conditions similar to those for siRNA molecules. As a non-limiting example, the method described above for selecting siRNA sequences can be used to select and generate aiRNA sequences.

[0204] In another embodiment, aiRNA duplexes of various lengths (e.g., about 10-25, 12-20, 12-19, 12-18, 13-17, or 14-17 base pairs, more typically 12, 13, 14, 15, 16, 17, 18, 19, or 20 base pairs) with overhangs on the 3' and 5' ends of the antisense strand can be designed to target a target mRNA. In certain examples, the sense strand of the aiRNA molecule is about 10-25, 12-20, 12-19, 12-18, 13-17, or 14-17 nucleotides in length, more typically 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length. In certain other examples, the antisense strand of the aiRNA molecule is about 15-60, 15-50, or 15-40 nucleotides in length, more typically about 15-30, 15-25, or 19-25 nucleotides in length, and preferably about 20-24, 21-22, or 21-23 nucleotides in length.

[0205] In some embodiments, the 5' antisense overhang contains one, two, three, four or more non-targeting nucleotides (e.g., "AA", "UU", "dTdT", etc.). In other embodiments, the 3' antisense overhang contains one, two, three, four or more non-targeting nucleotides (e.g., "AA", "UU", "dTdT", etc.). In certain aspects, the aiRNA molecules described herein can include one or more modified nucleotides, for example, in the double-stranded (duplex) region and / or the antisense overhang. As a non-limiting example, the aiRNA sequence can include one or more modified nucleotides described above for the siRNA sequence.

[0206] In certain embodiments, aiRNA molecules may include an antisense strand corresponding to an antisense strand of an siRNA molecule (e.g., one of the siRNA molecules described herein). In other embodiments, in the context of siRNA molecules, for example, genes associated with viral infection and survival, genes associated with metabolic diseases and disorders, genes associated with tumorigenesis and cell transformation, angiogenesis genes, immunomodulator genes (e.g., those associated with inflammation and autoimmune responses), ligand receptor genes, and genes associated with neurodegenerative disorders, aiRNA molecules can be used to silence the expression of any target gene described above. As a non-limiting example, antisense oligonucleotides can be used to silence the expression of SARS-CoV 2 genes encoding S (spike) proteins, E (envelope) proteins, M (membrane) proteins, or N (nucleocapsid) proteins.

[0207] D.miRNA

[0208] Typically, microRNA (miRNA) is a single-stranded RNA molecule of about 21-23 nucleotides in length that regulates gene expression. MiRNA is encoded by the gene of the DNA that transcribes them, but miRNA is not translated into protein (non-coding RNA); instead, each primary transcript (initial-miRNA) is processed into a short stem-loop structure called precursor miRNA and eventually becomes a functional mature miRNA. Mature miRNA molecules are partially or completely complementary to one or more messenger RNA (mRNA) molecules, and their main function is to downregulate gene expression.

[0209] The gene encoding miRNA is much longer than the mature miRNA molecule processed. First, miRNA is transcribed as an initial transcript or an initial-miRNA with a cap and a poly-A tail, and is processed into a short, about 70 nucleotide stem-loop structure called a precursor miRNA in the nucleus. This processing is carried out in animals by a protein complex called a microprocessor complex composed of a nuclease Drosha and a double-stranded RNA binding protein Pasha (Denli et al., Nature, 432: 231-235 (2004)). Then, these precursor miRNAs are processed into mature miRNAs in the cytoplasm by interacting with the endonuclease Dicer, which also initiates the formation of RNA-induced silencing complexes (RISC) (Bernstein et al., Nature, 409: 363-366 (2001)). The sense strand or antisense strand of DNA can be used as a template for the production of miRNA.

[0210] When Dicer cleaves the precursor miRNA stem-loop, two complementary short RNA molecules are formed, but only one is incorporated into the RISC complex. This chain is called the guide chain and is based on the stability of the 5' end, and is selected by the catalytically active RNA enzyme argonaute protein in the RISC complex (Preall et al., Curr.Biol., 16:530-535 (2006)). The remaining chain called the anti-guide or passenger chain is degraded into a RISC complex substrate (Gregory et al., Cell, 123:631-640 (2005)). After being incorporated into the active RISC complex, miRNA base pairs with its complementary mRNA molecule and induces target mRNA degradation and / or translation silencing.

[0211] Mammalian miRNA molecules are usually complementary to the position in the 3'UTR of the target mRNA sequence. In some examples, the annealing of miRNA to the target mRNA inhibits protein translation by blocking the protein translation mechanism. In some other examples, the annealing of miRNA to the target mRNA contributes to the cracking and degradation of the target mRNA by a method similar to RNA interference (RNAi). MiRNA can also target the methylation of the genomic position corresponding to the targeted mRNA. Generally, the miRNA functions related to the complement of proteins are collectively referred to as miRNP.

[0212] In some aspects, the miRNA molecule described herein is about 15-100, 15-90, 15-80, 15-75, 15-70, 15-60, 15-50 or 15-40 nucleotides in length, more generally about 15-30, 15-25 or 19-25 nucleotides in length, and preferably about 20-24, 21-22 or 21-23 nucleotides in length. In some other aspects, the miRNA molecule can include one or more modified nucleotides. As non-limiting examples, the miRNA sequence can include one or more modified nucleotides described for the siRNA sequence.

[0213] In some embodiments, in the context of siRNA molecules, for example, genes associated with viral infection and survival, genes associated with metabolic diseases and disorders, genes associated with tumorigenesis and cell transformation, angiogenesis genes, immunomodulator genes (such as those associated with inflammation and autoimmune responses), ligand receptor genes, and genes associated with neurodegenerative disorders, miRNA molecules can be used to silence the expression of any target gene set forth above. As a non-limiting example, miRNA can be used to silence the expression of SARS-CoV 2 genes encoding S (spike) protein, E (envelope) protein, M (membrane) protein, or N (nucleocapsid) protein.

[0214] In other embodiments, one or more agents that block the activity of a miRNA targeting an mRNA of interest are administered using lipid particles described herein. Examples of blockers include, but are not limited to, spacer oligonucleotides, locked nucleic acid oligonucleotides, and morpholino oligonucleotides. Such blockers can be directly bound to the miRNA or to the miRNA binding site on the target mRNA.

[0215] E. Antisense Oligonucleotides

[0216] In some embodiments, the nucleic acid component of lipid granules described herein is an antisense oligonucleotide related to a target gene or sequence. The term "antisense oligonucleotide" or "antisense" includes an oligonucleotide complementary to a polynucleotide sequence of targeting. Antisense oligonucleotides are single strands of DNA or RNA complementary to a selected sequence. Antisense RNA oligonucleotides prevent the translation of complementary RNA chains by binding to RNA. Antisense DNA oligonucleotides can be used for complementary (coding or non-coding) RNA of targeting specificity. If binding occurs, this DNA / RNA hybrid can be degraded by enzyme RNase H. In certain embodiments, antisense oligonucleotides include about 10 to about 60 nucleotides or about 15 to about 30 nucleotides. The term also encompasses antisense oligonucleotides that may not be precisely complementary to the desired target gene. Therefore, lipid granules described herein can be used in examples of using antisense to find non-target specific activity, or in examples of the most preferred specific use of antisense sequences containing one or more mismatches with the target sequence. Antisense oligonucleotides can contain natural nucleotides as well as non-natural or modified nucleotides (eg, modified nucleobases, modified internucleoside linkages and / or modified sugars such as those described herein).

[0217] Methods for producing antisense oligonucleotides are known in the art and can be readily adapted to produce antisense oligonucleotides targeting any polynucleotide sequence. The selection of an antisense oligonucleotide sequence specific for a given target sequence is based on analysis of the selected target sequence and the secondary structure, T m , binding energy and relative stability. Antisense oligonucleotides can be selected based on their ability to relatively not form dimers, hairpins or other secondary structures, and the structure will reduce or prohibit specific binding to target mRNA in host cells. The highly preferred target region of mRNA includes those regions that are in or near the AUG translation initiation codon and those sequences that are substantially complementary to the 5' region of mRNA. These secondary structure analyses and target site selection considerations can be carried out, for example, using OLIGO primer analysis software v.4 version (Molecular Biology Insights) and / or BLASTN2.0.5 algorithm software (Altschul et al., Nucleic Acids Res., 25:3389-402 (1997)).

[0218] In some embodiments, the antisense oligonucleotide components of lipid particles described herein can be used to inhibit the expression or replication of target genes. The target genes set forth in the context of siRNA molecules include but are not limited to genes related to viral infection and survival, genes related to metabolic diseases and illnesses (e.g., liver diseases and illnesses), genes related to tumorigenesis and cell transformation (e.g., cancer), angiogenesis genes, immunomodulator genes (e.g., genes related to inflammation and autoimmune responses), ligand receptor genes, and genes related to neurodegenerative disorders. As a non-limiting example, antisense oligonucleotides can hybridize with SARS-CoV-2 genes (e.g., orf1ab, S gene, ORF3a, E gene, M gene, ORF6, ORF7a, ORF8, N gene, or ORF10) and inhibit the expression or replication of genes.

[0219] F. Ribozyme

[0220] In some embodiments, the nucleic acid component of lipid granules described herein is a ribozyme. Ribozyme is an RNA-protein complex with a specific catalytic domain having endonuclease activity. For example, a large number of ribozymes have accelerated highly specific phosphate transfer reactions, often only cracking one of several phosphates in oligonucleotide substrates. This specificity is due to the requirement of combining the substrate interacting via specific base pairing with the internal guide sequence ("IGS") of the ribozyme before the chemical reaction.

[0221] At least 6 basic species of naturally occurring enzymatic RNA molecules are currently known. Each can catalyze the hydrolysis of trans RNA phosphodiester bonds under physiological conditions (and therefore can cleave other RNA molecules). Generally, enzymatic nucleic acids work by first binding to a target RNA. This binding occurs through the target binding portion of the enzymatic nucleic acid, which is kept in the enzymatic portion of the molecule in close proximity to the target RNA. Therefore, the enzymatic nucleic acid first recognizes and then binds to the target RNA through complementary base pairing, and once bound to the correct site, acts enzymatically to cut off the target RNA. Strategic cleavage of this target RNA will destroy its ability to directly synthesize coded proteins. After the enzymatic nucleic acid has bound and cleaved its RNA target, it is released from the RNA to find another target, and can repeatedly bind and cleave new targets.

[0222] Enzymatic nucleic acid molecules can be formed, for example, in a hammerhead, hairpin, hepatitis delta virus, group I intron, or RNase P RNA (associated with an RNA guide sequence) or Neurospora VS RNA motif. Specific examples of hammerhead motifs are described, for example, in Rossi et al., Nucleic Acids Res., 20:4559-65 (1992). Examples of hairpin motifs are described, for example, in EP 0360257, Hampel et al., Biochemistry, 28:4929-33 (1989); Hampel et al., Nucleic Acids Res., 18:299-304 (1990); and U.S. Pat. No. 5,631,359. Examples of hepatitis delta virus motifs are described, for example, in Perrotta et al., Biochemistry, 31:11843-52 (1992). Examples of RNase P motifs are described, for example, in Guerrier-Takada et al., Cell, 35:849-57 (1983). Examples of Neurospora VS RNA motifs are described, for example, in Saville et al., Cell, 61:685-96 (1990); Saville et al., Proc. Natl. Acad. Sci. USA, 88:8826-30 (1991); Collins et al., Biochemistry, 32:2795-9 (1993). Examples of group I introns are described, for example, in U.S. Pat. No. 4,987,071. An important feature of enzymatic nucleic acid molecules is that they have a specific substrate binding site that is complementary to one or more target gene DNA or RNA regions, and that they have a nucleotide sequence within or around the substrate binding site that exerts RNA cleavage activity on the molecule. Therefore, ribozyme constructs need not be limited to the specific motifs described herein.

[0223] Methods for producing ribozymes targeting any polynucleotide sequence are known in the art. Ribozymes can be designed as described in, for example, PCT Publication Nos. WO 93 / 23569 and WO 94 / 02595, and synthesized to be tested in vitro and / or in vivo as described therein.

[0224] Ribozyme activity can be optimized by varying the length of the ribozyme binding arms or chemically synthesizing ribozymes with modifications that protect them from degradation by serum ribonucleases (see, e.g., PCT Publication Nos. WO 92 / 07065, WO 93 / 15187, WO 91 / 03162, and WO 94 / 13688; EP 92110298.4; and U.S. Pat. No. 5,334,711, which describe various chemical modifications that can be made to the sugar moieties of enzymatic RNA molecules), modifications that enhance their efficacy in cells, and removal of the Stem II base to shorten RNA synthesis time and reduce chemical requirements.

[0225] G. Immunostimulatory Oligonucleotides

[0226] In some embodiments, the nucleic acid component of the lipid granules described herein is an immunostimulatory oligonucleotide (ISS; single-stranded or double-stranded) capable of inducing an immune response when administered to a subject, and the subject can be a mammal such as a human. ISS includes, for example, certain palindromic sequences that lead to a hairpin secondary structure (see, Yamamoto et al., J. Immunol., 148:4072-6 (1992)) or CpG motifs and other known ISS features (such as poly-G domains; see; PCT Publication No. WO 96 / 11266).

[0227] Immunostimulatory nucleic acids are considered to be non-sequence specific when they are not required to specifically bind to a target sequence and reduce the expression of the target sequence in order to elicit an immune response. Therefore, some immunostimulatory nucleic acids may comprise sequences corresponding to regions of naturally occurring genes or mRNAs, but they may still be considered to be non-sequence specific immunostimulatory nucleic acids.

[0228] In one embodiment, the immunostimulatory nucleic acid or oligonucleotide comprises at least one CpG dinucleotide. The oligonucleotide or CpG dinucleotide can be unmethylated or methylated. In another embodiment, the immunostimulatory nucleic acid comprises at least one CpG dinucleotide with methylated cytosine. In one embodiment, the nucleic acid comprises a single CpG dinucleotide, wherein the cytosine in the CpG dinucleotide is methylated. In an alternative embodiment, the nucleic acid comprises at least two CpG dinucleotides, wherein at least one cytosine in the CpG dinucleotide is methylated. In other embodiments, each cytosine present in the CpG dinucleotide in the sequence is methylated. In another embodiment, the nucleic acid comprises multiple CpG dinucleotides, wherein at least one CpG dinucleotide comprises methylated cytosine. In certain embodiments, the oligonucleotide for compositions and methods described herein has a phosphodiester ("PO") backbone or a phosphorothioate ("PS") backbone, and / or has at least one methylated cytosine residue in the CpG motif.

[0229] VI. Preparation of lipid particles

[0230] The lipid particles described herein can be formed by any method known in the art in which nucleic acids such as mRNA can be encapsulated and protected from degradation, including but not limited to continuous mixing methods and direct dilution methods.

[0231] In some embodiments, lipid particles described herein are produced via a continuous mixing method, such as a method comprising the following steps: providing an aqueous solution comprising nucleic acid in a first tank, providing an organic lipid solution in a second tank, and mixing the aqueous solution with the organic lipid solution so that the organic lipid solution mixes with the aqueous solution, so that lipid particles encapsulated with nucleic acid are substantially instantaneously produced. This method and a device for implementing the method are described in U.S. Patent Publication No. 20040142025.

[0232] Continuously introduce lipid and buffer solution into the mixed environment as the action in the mixing chamber causes the continuous dilution of lipid solution with buffer solution, thereby substantially instantaneously producing lipid particles when mixing. As used herein, the phrase "continuous dilution of lipid solution with buffer solution" (and variants) generally means fully and rapidly diluting lipid solution in the hydration process with enough power to realize vesicle generation. In the presence of buffer solution (i.e., aqueous solution), the organic lipid solution is mixed with the organic lipid solution by making the aqueous solution comprising nucleic acid experience continuous stepwise dilution to produce lipid particles.

[0233] The lipid granule formed using the continuous mixing method generally has a size of about 40nm to about 150nm, about 50nm to about 150nm, about 60nm to about 130nm, about 70nm to about 110nm or about 70nm to about 90nm.Therefore the formed particle can not gather, and optionally its size is set to realize uniform particle size.

[0234] In some embodiments, lipid granules described herein are produced via direct dilution method, and the direct dilution method comprises forming lipid granule solution and immediately and directly introducing lipid granule solution into the collection container containing the dilution buffer of the amount of control.In certain embodiments, the collection container comprises one or more elements configured to stir the content of the collection container to promote dilution.In one embodiment, the amount of the dilution buffer present in the collection container is substantially equal to the volume of the lipid granule solution introduced therein.As non-limiting example, when being introduced into the collection container containing the dilution buffer of equal volume, the lipid granule solution in 45% ethanol will advantageously produce smaller particles.

[0235] In some embodiments, lipid granules described herein are produced via direct dilution method, wherein the third tank fluid containing dilution buffer is connected to the second mixing zone. In this embodiment, the lipid granule solution formed in the first mixing zone is immediately and directly mixed with the dilution buffer in the second mixing zone. In certain embodiments, the second mixing zone includes a T-connector, and the T-connector is arranged so that the lipid granule solution and the dilution buffer meet and flow in reverse 180 °; however, for example, a connector providing a smaller angle of about 27 ° to about 180 ° can be used. The pump mechanism delivers the buffer of the controllable flow rate to the second mixing zone. In one embodiment, the flow rate of the dilution buffer provided to the second mixing zone is controlled to be substantially equal to the flow rate into which the lipid granule solution is introduced from the first mixing zone. This embodiment advantageously allows more control of the flow of the dilution buffer mixed by the lipid granule solution in the second mixing zone, and therefore also controls the concentration of the lipid granule solution in the buffer in the whole second mixing process. This control of the dilution buffer flow rate advantageously allows the formation of a small particle size under a reduced concentration.

[0236] These methods and apparatus for performing these direct dilution methods are described in US Patent Publication No. 20070042031.

[0237] The lipid granule formed using the direct dilution method generally has a size of about 40nm to about 150nm, about 50nm to about 150nm, about 60nm to about 130nm, about 70nm to about 110nm or about 70nm to about 90nm.Therefore the formed particle can not assemble, and optionally its size is set to realize uniform particle size.

[0238] If desired, the lipid particles described herein can be sized by any method available to those skilled in the art. Sizing can be performed so as to achieve a desired size range and a relatively narrow particle size distribution.

[0239] Several techniques can be used to set the particles to a desired size. A method for setting the size used for liposomes and equally applicable to the particles of the present invention is described in U.S. Patent No. 4,737,323. Ultrasound of a particle suspension by bath or probe ultrasound produces particles that are gradually reduced in size to a size less than about 50 nm. Homogenization is another method that relies on shear energy to break larger particles into smaller particles. In a typical homogenization procedure, the particles are passed through a standard emulsion homogenizer until a selected particle size is observed, typically between about 60 nm and about 80 nm. In both methods, the particle size distribution can be monitored by conventional laser beam particle size identification or QELS.

[0240] Extrusion of particles through small pore polycarbonate membranes or asymmetric ceramic membranes is also an effective method for reducing particle size to a relatively well-defined size distribution. Typically, the suspension is cycled through the membrane one or more times until the desired particle size distribution is achieved. Gradual size reduction can be achieved by extruding particles through successively smaller and smaller pore membranes.

[0241] In some embodiments, the nucleic acid and lipid ratio (mass / mass ratio) in the lipid granule formed are about 0.01 to about 0.2, about 0.02 to about 0.1, about 0.03 to about 0.1 or about 0.01 to about 0.08. The ratio of starting material also falls within this scope. In other embodiments, the lipid granule preparation has used about 400 μ g nucleic acid / 10 mg TL, or about 0.01 to about 0.08 nucleic acid and lipid mass ratio, for example about 0.04 nucleic acid and lipid mass ratio, and it is corresponding to 1.25 mg TL / 50 μ g nucleic acid. In certain embodiments, the nucleic acid that granule has: lipid mass ratio is about 0.08.

[0242] In other embodiments, the lipid to nucleic acid ratio (mass / mass ratio) in the formed lipid particles is about 1 (1:1) to about 100 (100:1), about 5 (5:1) to about 100 (100:1), about 1 (1:1) to about 50 (50:1), about 2 (2:1) to about 50 (50:1), about 3 (3:1) to about 50 (50:1), about 4 (4:1) to about 50 (50:1), about 5 (5:1) to about 50 (50:1), about 1 (1:1) to about 25 (25:1), about 2 (2:1) to about 25 (25:1). , about 3 (3:1) to about 25 (25:1), about 4 (4:1) to about 25 (25:1), about 5 (5:1) to about 25 (25:1), about 5 (5:1) to about 20 (20:1), about 5 (5:1) to about 15 (15:1), about 5 (5:1) to about 10 (10:1), about 5 (5:1), 6 (6:1), 7 (7:1), 8 (8:1), 9 (9:1), 10 (10:1), 11 (11:1), 12 (12:1), 13 (13:1), 14 (14:1), or 15 (15:1). The ratio of the starting materials also falls within this range.

[0243] VII. Administration of lipid particles

[0244] Once formed, lipid particles described herein can be used to introduce nucleic acids such as mRNA into cells. Therefore, the present invention also provides methods for introducing nucleic acids such as mRNA into cells. The method is performed in vitro or in vivo, first forming particles, and then contacting the particles with cells for a period of time sufficient to deliver the nucleic acid to the cells.

[0245] Lipid granules described herein can be absorbed into almost any cell type that mixes or contacts with them. Once absorbed, the granules can be endocytosed by a part of the cell, exchange lipids with the cell membrane, or merge with the cell. The transfer or incorporation of the nucleic acid portion of the granule can occur via any of these approaches. Specifically, when fusion occurs, the granule membrane is incorporated into the cell membrane, and the content of the granule is combined with the intracellular fluid.

[0246] Lipid granules described herein can be used individually or mixed with a pharmaceutically acceptable carrier (e.g., normal saline or phosphate buffer) selected according to route of administration and standard pharmaceutical practice. Typically, normal buffered saline (e.g., 135-150mM NaCl) is used as a pharmaceutically acceptable carrier. Other suitable carriers include, for example, water, buffered water, 0.4% saline, 0.3% glycine, etc., including glycoproteins such as albumin, lipoprotein, globulin, etc. for enhanced stability. Additional suitable carriers are described in, for example, Remington's PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, PA, the 17th edition (1985). As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic agents and absorption delay agents, buffers, carrier solutions, suspensions, colloids, etc. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce allergies or similar adverse reactions when applied to people.

[0247] The pharmaceutically acceptable carrier is typically added after particle formation. Thus, after particle formation, the particles can be diluted into a pharmaceutically acceptable carrier such as normal buffered saline.

[0248] The particle concentration in the pharmaceutical preparation can vary widely, for example, from less than about 0.05%, typically or at least about 2 to about 5%, to as much as about 10 to about 90% by weight, and can be selected primarily by fluid volume, viscosity, etc., according to the specific mode of administration selected. For example, the concentration can be increased to reduce the fluid load associated with the treatment. This can be particularly desirable in patients with congestive heart failure or severe hypertension associated with atherosclerosis. Alternatively, the particles consisting of irritating lipids can be diluted to low concentrations to reduce inflammation at the site of administration.

[0249] The pharmaceutical composition described herein can be sterilized by conventional well-known sterilization techniques. The aqueous solution can be packaged for use or filtered and lyophilized under aseptic conditions, and the lyophilized preparation is combined with a sterile aqueous solution before administration. When it is necessary to approach physiological conditions, the composition can contain pharmaceutically acceptable auxiliary substances, such as pH adjusting agents and buffers, tension regulators, etc., such as sodium acetate, sodium lactate, sodium chloride, potassium chloride and calcium chloride. In addition, the particle suspension can include a lipid protective agent that protects lipids from free radicals and lipid peroxidation damage during storage. Lipophilic free radical quenchers such as alpha-tocopherol and water-soluble iron-specific chelating agents such as ferroamine are suitable.

[0250] A. In vivo administration

[0251] In some embodiments, the lipid particles described herein are delivered to, for example, distal target cells via a body system such as circulation and administered to a subject. In certain embodiments, the disclosure provides fully encapsulated lipid particles that protect nucleic acids from nuclease degradation in serum, are non-immunogenic, small in size, and suitable for repeated administration.

[0252] For in vivo administration, it can be administered in any manner known in the art, such as by injection, oral administration, inhalation (e.g., intranasal or intratracheal), transdermal application, or rectal administration. Administration can be accomplished via a single dose or divided doses. The pharmaceutical composition can be administered parenterally, i.e., intraarticularly, intravenously, intraperitoneally, subcutaneously, or intramuscularly. In some embodiments, the pharmaceutical composition is administered intravenously or intraperitoneally by bolus injection (see, e.g., U.S. Patent No. 5,286,634). Intracellular nucleic acid delivery is also discussed in Straubringer et al., Methods Enzymol., 101: 512 (1983); Mannino et al., Biotechniques, 6: 682 (1988); Nicolau et al., Crit. Rev. Ther. Drug Carrier Syst., 6: 239 (1989); and Behr, Acc. Chem. Res., 26: 274 (1993). Other methods of administering lipid-based therapeutic agents are described in, for example, U.S. Pat. Nos. 3,993,754; 4,145,410; 4,235,871; 4,224,179; 4,522,803; and 4,588,578. The lipid particles can be administered by direct injection at the site of disease or by injection at a site away from the site of disease (see, for example, Culver, HUMAN GENE THERAPY, Mary Ann Liebert, Inc., Publishers, New York. Pages 70-71 (1994)).

[0253] The compositions described herein, alone or in combination with other suitable components, can be prepared into aerosol formulations (i.e., they can be "nebulized") to be administered via inhalation (e.g., intranasally or intratracheally) (see, Brigham et al., Am. J. Sci., 298:278 (1989)). Aerosol formulations can be placed in pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, etc.

[0254] In certain embodiments, pharmaceutical composition can be delivered by intranasal spray, suction and / or other aerosol delivery vehicles. The method for directly delivering nucleic acid composition to lung via nasal aerosol spray has been described in, for example, U.S. Patent No. 5,756,353 and 5,804,212. Similarly, intranasal microparticle resin and lysophosphatidyl-glycerol compound delivery drugs (U.S. Patent No. 5,725,871) are also well known in the pharmaceutical field. Similarly, transmucosal drug delivery in the form of polytetrafluoroethylene carrier matrix is ​​described in U.S. Patent No. 5,780,045.

[0255] Formulations suitable for parenteral administration, such as by intraarticular (in a joint), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes include aqueous and nonaqueous isotonic sterile injection solutions, which may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and nonaqueous sterile suspensions, which may include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In specific embodiments, the composition is administered intravenously (e.g., by intravenous infusion), intramuscularly, pulmonary, orally, topically, intranasally, intracerebrally, intraperitoneally, intravesically, or intrathecally.

[0256] Typically, when intravenously administered, lipid granule preparations are formulated with a suitable pharmaceutical carrier. Many pharmaceutically acceptable carriers can be used in compositions and methods described herein. Suitable preparations can be found, for example, in Remington's PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, PA, the 17th edition (1985). Various aqueous carriers can be used, such as water, buffered water, 0.4% saline, 0.3% glycine, etc., and glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc. can be included. Typically, physiological buffered saline (135-150mM NaCl) is used as a pharmaceutically acceptable carrier, but other suitable carriers will also meet the needs. These compositions can be sterilized by conventional liposome sterilization techniques such as filtration. When approaching physiological conditions, the composition can contain pharmaceutically acceptable auxiliary substances, such as pH adjusting agents and buffers, tension adjusting agents, wetting agents, etc., such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc. These compositions can be sterilized using the above-mentioned technology, or alternatively they can be produced under aseptic conditions. The resulting aqueous solution can be packaged for use or filtered and lyophilized under aseptic conditions, and the lyophilized preparation is combined with a sterile aqueous solution before administration.

[0257] In some applications, lipid particles described herein can be delivered to a subject via oral administration. Particles can be merged with excipients and used in the form of ingestible tablets, buccal tablets, lozenges, capsules, pills, lozenges, elixirs, mouthwashes, suspensions, oral sprays, syrups, wafers, etc. (see, for example, U.S. Patent Nos. 5,641,515, 5,580,579 and 5,792,451). These oral dosage forms can also contain adhesives, gelatin; excipients, lubricants and / or flavoring agents. When the unit dosage form is a capsule, it can contain a liquid carrier in addition to the material described above. Various other materials can exist as coatings or otherwise change the physical form of dosage units. Of course, any material used to prepare any unit dosage form should be pharmaceutically pure and substantially nontoxic under the amount used.

[0258] Usually, these oral preparations can contain at least about 0.1% lipid particles or more, although the percentage of particles can certainly change, and can be conventionally about 1% or about 2% and about 60% or about 70% or more of the weight or volume of total preparation.Naturally, the amount of particles in each treatment useful composition can be prepared in a manner suitable for dosage to be obtained in any given unit dose of compound.Prepare the technician in this pharmaceutical preparation field will think of factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life and other pharmacological considerations, and similarly, various dosages and treatment regimens can be desired.

[0259] Formulations suitable for oral administration may consist of: (a) a liquid solution, such as an effective amount of lipid particles containing nucleic acids (e.g., mRNA) suspended in a diluent such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of lipid particles containing nucleic acids (e.g., mRNA) in liquid, solid, granular or gelatin; (c) a suspension in an appropriate liquid; and (d) a suitable emulsion. Tablet forms may include lactose, sucrose, mannitol, sorbitol, calcium phosphate, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid and other excipients, colorants, fillers, binders, diluents, buffers, moisturizers, preservatives, flavorings, dyes, disintegrants and one or more pharmaceutically compatible carriers. Lozenge forms may include lipid particles containing nucleic acids (e.g., mRNA) in a flavoring such as sucrose, as well as lozenges containing lipid particles in an inert matrix such as gelatin and glycerol or sucrose, and acacia emulsions, gels, and the like containing, in addition to lipid particles, carriers known in the art.

[0260] In another example of their use, lipid particles can be incorporated into a wide range of topical dosage forms. For example, suspensions containing lipid particles can be formulated into and applied in the form of gels, oils, emulsions, topical creams, pastes, ointments, lotions, foams, mousses, etc.

[0261] When preparing pharmaceutical preparations of the lipid particles described herein, it is preferred to use large quantities of such particles that have been purified to reduce or eliminate empty particles or particles having nucleic acids associated with the outer surface.

[0262] The methods described herein can be practiced in a variety of hosts. Preferred hosts include mammalian species, such as primates (e.g., humans and chimpanzees and other non-human primates), dogs, cats, horses, cattle, sheep, goats, rodents (e.g., rats and mice), lagomorphs, and pigs.

[0263] The amount of particles administered will depend on the ratio of nucleic acid (e.g., mRNA) to lipid, the specific nucleic acid used, the disease or condition being treated, the age, weight and condition of the subject, and the judgment of the clinician, but will generally be between about 0.01 mg / kg and about 50 mg / kg body weight, between about 0.1 mg / kg and about 5 mg / kg body weight, or about 100 mg / kg per administration (e.g., injection). 8 -10 10 A particle.

[0264] B. In vitro administration

[0265] For in vitro applications, nucleic acids (e.g., mRNA) can be delivered to any cell grown in culture, whether of plant or animal origin, vertebrate or invertebrate, and of any tissue or type. In certain embodiments, the cell is an animal cell, e.g., a mammalian cell, such as a human cell.

[0266] When carried out in vitro, the contact between the cell and the lipid particles usually occurs in a biocompatible culture medium. The concentration of the particles can be widely changed depending on the specific application, but is generally about 1 μmol and about 10 mmol. The treatment of cells with lipid particles is usually carried out at physiological temperature (about 37 ° C) for about 1 to about 48 hours, for example, about 2 to about 4 hours.

[0267] In some embodiments, the lipid particle suspension is added to cells at a density of about 10 3 to about 10 5 cells / ml, for example, about 2×10 4 The concentration of the suspension added to the cells may be about 0.01 to 0.2 μg / ml, such as about 0.1 μg / ml.

[0268] Using the endosomal release parameter (ERP) assay, the delivery efficiency of lipid particles can be optimized. ERP assays are described in U.S. Patent Publication No. 20030077829. More specifically, the purpose of ERP assays is to distinguish the effects of various cationic lipids and assisting lipid components based on their relative effects on the binding / absorption or fusion / destabilization of endosomal membranes. This assay allows people to quantitatively determine how each component of lipid particles affects the delivery efficiency, thereby optimizing lipid particles. Typically, ERP assays measure the expression of reporter proteins (e.g., luciferase, β-galactosidase, green fluorescent protein (GFP), etc.), and in some examples, lipid particle formulations optimized for expression plasmids will also be suitable for encapsulating other types of nucleic acids, such as mRNA. In some examples, ERP assays may be suitable for measuring the transcription or translation downregulation of target sequences in the presence or absence of interfering RNA (e.g., siRNA). In other examples, ERP assays may be suitable for measuring the expression of target proteins in the presence or absence of mRNA. By comparing the ERP of each of the various lipid particles, people can easily determine the optimized system, such as the lipid particles with maximum absorption in cells.

[0269] C. Cells for delivery of lipid particles

[0270] Compositions and methods described herein are used for treating various cell types in vivo and in vitro. Suitable cells include, for example, hematopoietic precursor (stem) cells, fibroblasts, keratinocytes, hepatocytes, immune cells, endothelial cells, skeletal muscle and smooth muscle cells, osteoblasts, neurons, dormant lymphocytes, terminally differentiated cells, slow-circulating or non-circulating primary cells, parenchymal cells, lymphoid cells, epithelial cells, osteocytes, etc. In some embodiments, lipid particles comprising nucleic acid (e.g., mRNA) are delivered to immune cells, such as antigen presenting cells (e.g., dendritic cells, macrophages, B cells) and T cells (e.g., helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells). In some embodiments, lipid particles comprising a nucleic acid (e.g., siRNA) are delivered to cancer cells, such as lung cancer cells, colon cancer cells, rectal cancer cells, anal cancer cells, bile duct cancer cells, small intestine cancer cells, stomach (gastric) cancer cells, esophageal cancer cells, gallbladder cancer cells, liver cancer cells, pancreatic cancer cells, appendix cancer cells, breast cancer cells, ovarian cancer cells, cervical cancer cells, prostate cancer cells, kidney cancer cells, cancer cells of the central nervous system, glioblastoma tumor cells, skin cancer cells, lymphoma cells, choriocarcinoma tumor cells, head and neck cancer cells, osteogenic sarcoma tumor cells, and blood cancer cells.

[0271] In vivo delivery of lipid particles comprising nucleic acids is applicable to cells targeting any cell type. The method and composition can be employed for cells of a wide variety of vertebrates, including mammals such as, for example, dogs, cats, horses, cattle, sheep, goats, rodents (e.g., mice, rats and guinea pigs), lagomorphs, pigs and primates (e.g., monkeys, chimpanzees and humans).

[0272] Example

[0273] The present disclosure will be described in more detail by specific examples.The following examples are provided for illustrative purposes only and are not intended to limit the present disclosure in any way.

[0274] Example 1. Synthesis of ditetradecylamine for poly(alkyloxazoline)-lipid conjugates.

[0275] Ditetradecylamine (5) was synthesized according to the scheme shown below.

[0276]

[0277] Synthesis of 4-methyl-N,N-di-tetradecylbenzenesulfonamide (3). KCO (20.18 g, 146.0 mmol), p-toluenesulfonamide (1) (5.00 g, 29.2 mmol) and 1-bromotetradecane (2) (21.7 ml, 73.0 mmol) were heated to reflux in DMF (75 ml) for 20 hours. The reaction was cooled to room temperature, diluted with EtO (100 ml) and filtered. The filtrate was washed with HO (50 ml) and the aqueous layer was stripped with EtO (100 ml). The combined organics were dried (NaSO), filtered, concentrated in vacuo and the residue was purified by automated flash chromatography (DCM / hexane 40 / 60) to give 4-methyl-N,N-di-tetradecyl-p-toluenesulfonamide (3) (15.86 g, 96%).

[0278] Synthesis of ditetradecylamine (5). 4-Methyl-N,N-ditetradecylbenzenesulfonamide (3) (10 g, 17.7 mmol) in THF (5 ml) was added to lithium napthalenide (prepared by stirring naphthalene (4) (11.36 g, 88.7 mmol) and lithium metal (0.92 g, 133.0 mmol) in THF (40 ml) at room temperature for 1 hour) at 0°C, and the reaction was stirred at room temperature for 1 hour. MeOH (4 ml) was added, followed by H2O (50 ml), and the mixture was extracted with ether (100 ml). The organics were dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by automated flash chromatography (EtOAc / Hex (50:50)) to give ditetradecylamine (5) (4.85 g, 66.7%).

[0279] Example 2. Synthesis of 2,3-bis(tetradecyloxy)propan-1-amine for poly(alkyloxazoline)-lipid conjugates.

[0280] 2,3-Bis(tetradecyloxy)propan-1-amine (TFA salt) (10) was synthesized according to the following scheme.

[0281]

[0282] Synthesis of tert-butyl (2,3-dihydroxypropyl)carbamate (8). Di-tert-butyl dicarbonate (7) (14.23 g, 65.2 mmol) and 3-amino-1,2-propanediol (6) (5.4 g, 59.3 mmol) were stirred in DCM / MeOH (1:1) at room temperature for 16 hours. The reaction was concentrated in vacuo to give 8 (11.25 g, 99%), which was used without purification.

[0283] Synthesis of tert-butyl (2,3-bis (tetradecyloxy) propyl) carbamate (9). At 0 ° C, tert-butyl (2,3-dihydroxypropyl) carbamate (8) (5g, 26.2mmol), tetradecane bromo (21.75g, 78.5mmol) and TBAHS (4.44g, 13.1mmol) were stirred in toluene (20mL). NaOH (15mL, 50% w / v) was added, and the two-phase mixture was stirred vigorously for 18 hours and allowed to warm to room temperature. The reactant was diluted with water and extracted with hexane. The combined organic matter was washed (brine), dried (MgSO4), filtered and concentrated in vacuo. The crude material was subjected to chromatography (10% EtOAc-hexane) to obtain tert-butyl (2,3-bis (tetradecyloxy) propyl) carbamate (9) (quantitative).

[0284] Synthesis of 2,3-bis(tetradecyloxy)propan-1-amine (TFA salt) (10). Tert-butyl (2,3-bis(tetradecyloxy)propyl)carbamate (9) prepared in step 2 was stirred in TFA / DCM (1:1) at room temperature for 2 hours. The reaction was concentrated in vacuo to give 2,3-bis(tetradecyloxy)propan-1-amine (TFA salt) (10) (8.3 g, quantitative), which was used without purification.

[0285] Example 3. Synthesis of poly(alkyloxazoline)-lipid conjugates.

[0286] For conjugate (11), N-alkylated thiopropionamide POZ lipid was synthesized as shown below.

[0287]

[0288] The reagent was stirred at room temperature for 16 hours in DCM. Reactant was concentrated in a vacuum and residue was purified by automatic flash chromatography (0-25% MeOH / DCM). Similar products containing components were merged and concentrated in a vacuum. Residue was absorbed in the DCM of minimum volume and Et2O was added to produce precipitate, which was recovered by filtration to obtain 11 (38 mg, 11.7%). 1 H NMR (400MHz, CDCl3) δ3.47 (bs, 159H), 2.46-2.26 (m, 83H), 1.76 (s, 33H), 1.3 (m, 33H), 1.14 (m, 122H), 0.90 (m, 6H).

[0289] The following lipid conjugates were prepared using similar methods as described above with the appropriate amines.

[0290]

[0291] Compound (12). 1 H NMR (400MHz, CDCl3). 3.46 (bs, 126H), 2.46-2.25 (m, 57H), 1.78 (S, 9H), 1.27 (m.24H), 1.15 (m, 99H), 0.90 (t, J=4Hz), 6H).

[0292]

[0293] Compound (13). 1H NMR (400MHz, CDCl3). 3.46 (bs, 145H), 2.46-2.26 (m, 78H), 1.72 (bs, 24H), 1.25 (m, 21H), 1.14 (m, 112H), 0.9 (m, 3H).

[0294]

[0295] Compound (14). 1 H NMR(400MHz, CDCl3).3.46(bs, 128H), 2.85(m, 2H), (2.5-2.24)(m, 54H), 1 .78 (s, 32H), 1.57 (m, 4H), 1.26 (m, 32H), 1.12 (m, 92H), 0.89 (t, J=4Hz, 6H).

[0296]

[0297] Compound (15). 1 H NMR (400MHz, CDCl3) 3.49 (bs, 136H), 2.46-2.26 (m, 60H), 1.7 (bs, 20H), 1.57 (m, 5H), 1.27 (m, 30H), 1.14 (bs, 100H), 0.89 (t, 6H, J=4Hz).

[0298] Example 4. General methods for lipid nanoparticle preparation and characterization.

[0299] Lipid Nanoparticle (LNP) Formulation

[0300] The lipid solution contained 4 components: a polymer-conjugated lipid, an ionizable cationic lipid (e.g., (6Z, 16Z)-12-((Z)-dec-4-en-1-yl)docosa-6,16-dien-11-yl 5-(dimethylamino)-pentanoate), cholesterol, and a phospholipid (e.g., DSPC). The lipid stock solution was prepared using the lipid properties and molar ratios as described to achieve a total concentration of approximately 7 mg / mL in 100% ethanol. Firefly luciferase (Luc) mRNA (TriLink Biotechnologies, L-7202) or ovalbumin (OVA) mRNA (TriLink Biotechnologies, L-7210) was diluted in acetate, pH 5 buffer and nuclease-free water to obtain a target concentration of 0.366 mg / mL of mRNA in 100 mM acetate (pH 5). Equivolumetric lipid and nucleic acid solution are mixed by T-connector with the flow rate of 400mL / min, and diluted with about 4 volumes of PBS (pH7.4).Preparation is placed in Slide-A-Lyzer dialysis unit (MWCO 10,000), and dialyzed overnight with 10mM Tris, 500mM NaCl, pH 8 buffer.After dialysis, VivaSpin concentrator unit (MWCO 100,000) is used to concentrate the preparation to about 0.5mg / mL, and dialyzed overnight with 5mM Tris, 10% sucrose, pH 8 buffer.Preparation is filtered through 0.2 μm syringe filter and stored at -80 ° C until use.Nucleic acid concentration is determined by RiboGreen assay.Particle size (hydrodynamic diameter) and polydispersity index (PDI) are measured by dynamic light scattering using Malvern Nano Series Zetasizer.

[0301] In vivo testing of lipid nanoparticles via intravenous administration (luciferase model)

[0302] LNP formulations encapsulating firefly luciferase were injected intravenously into female BALB / c mice (6-8 weeks old) at 0.5 mg / kg. On the day of injection, the LNP stock solution was filtered and diluted to the desired dose concentration with phosphate buffered saline, pH 7.4. Six hours after administration, the animals were anesthetized with a lethal dose of ketamine / xylazine. Blood samples were collected into EDTA microcontainer tubes and centrifuged at 16,000xg for 5 minutes at 4°C. All plasma samples were stored at -80°C until cytokine analysis was performed. Liver samples were collected, weighed, and quickly frozen in liquid nitrogen. Liver samples were stored at -80°C in The tubes were kept in the refrigerator until analysis of luciferase activity.

[0303] Cytokine analysis

[0304] The production of proinflammatory cytokines (i.e., monocyte chemoattractant protein-1, MCP-1) was measured by ELISA using a paired monoclonal antibody from BD Biosciences. The plate was coated with capture antibody and stored overnight at 2 to 8°C. The next day, the plate was closed with 1x PBS containing 10% FBS and the test sample was added. After washing three times, the detection antibody was added and incubated for 1 hour. After incubation and washing, TMB substrate was added for color development, and the reaction was terminated with sulfuric acid. The plate was read at 450 / 570OD.

[0305] Luciferase activity assay

[0306] Frozen liver aliquots were thawed and used Homogenizer is homogenized in 1mL of 1xCCLR (cell culture lysis reagent).The homogenate is centrifuged at 16,000rpm for 10 minutes at 4°C.Twenty (20) μL of supernatant is loaded into 96-well white plates, and luminescence is measured after adding luciferase reagent (Promega luciferase assay system).Luciferase activity is measured by comparing the luminescence of the homogenate sample with luciferase protein standards.In order to solve any quenching of the luminescence caused by the components in the liver homogenate, luciferase is added to the liver homogenate of untreated animals and the resulting luminescence is measured.Quenching factor is applied to all samples to obtain the luciferase activity value of correction, and normalization analysis is performed to the tissue per unit mass.

[0307] In vivo testing of lipid nanoparticles via intramuscular administration (ovalbumin immunogenicity model)

[0308] On day 0 (primary) and day 21 (boost), LNP formulations encapsulating OVA mRNA were administered intramuscularly to BALB / c mice (7-8 weeks old) at a dose of 1 μg. Blood samples were collected into EDTA microcontainer tubes before administration and on days 7, 14, 21, and 28. On day 35, animals were anesthetized with a lethal dose of ketamine / xylazine. Blood samples were collected into EDTA microcontainer tubes and centrifuged at 16,000xg for 5 minutes at 4°C. All plasma samples were stored at -80°C until anti-OVA IgG ELISA was performed. Spleen samples were also collected at the endpoint time point, and spleen cells were collected for ELISpot determination.

[0309] Anti-OVA IgG analysis

[0310] The ELISA method was used to measure the production of anti-OVA IgG antibodies. The plates were coated with ovalbumin and stored overnight at 2 to 8°C. The next day, the plates were blocked with PBS containing 10% FBS and the samples were added. After washing, the secondary antibody was added and incubated for 2 hours at room temperature. After incubation, the plates were washed and TMB substrate was added for color development. The reaction was stopped with 2N sulfuric acid and the plates were read at 450 / 570OD.

[0311] ELISpot analysis

[0312] At the endpoint time point, spleen samples were collected from the animals and splenocytes were isolated. ELISpot plates were prepared by washing the plates and incubating with medium for at least 30 minutes. After incubation, the medium was removed and the stimulant was added. Cells were added and incubated overnight at 37°C. After overnight incubation, cells were removed and the plates were washed. Detection antibody was added and then incubated for 2 hours at room temperature. The plates were washed and streptavidin-HRP antibody was added. After incubation for 1 hour at room temperature, the plates were washed and TMB substrate was added for color development. The reaction was stopped with 2N sulfuric acid and the plates were read at 450 / 570OD.

[0313] Example 5. Particle properties of LNP formulations containing poly(2-ethyl-2-oxazoline) (PEOZ)-lipid conjugates.

[0314] The PEOZ lipid of about 5000Da with different alkyl chain lengths and connectors is formulated into LNP and compared with two PEG-lipid controls.Luc mRNA is used as payload.Although PEOZ 5000 polymer has hydrophobicity, it is incorporated into LNP and causes the formation of stable particles.Importantly, the physicochemical characteristics (table 1) suitable for LNP prepared with PEG2000-C-DMA and commercially available PEG-DMG lipids of LNP prepared with different PEOZ lipid chemicals are reported.

[0315] Table 1. Particle properties of LNP formulations containing various PEOZ lipids

[0316]

[0317] %EE = encapsulation efficiency; PDI = polydispersity

[0318] Embodiment 6. contains the performance of the LNP of PEOZ-lipid conjugate in intravenous mouse model.The LNP preparation carrying luciferase mRNA payload and PEOZ5000 lipid is compared with the benchmark control (PEG2000-C-DMA and PEG-DMG), for the activity in luciferase mouse model after intravenous administration.After using 6h, PEOZ lipid preparation mediates high-level luciferase activity in liver, reports the activity (table 2) of being equivalent or improved compared with control.In addition, compared with commercially available PEG-DMG, these PEOZ lipid preparations report lower luciferase expression in spleen, show lower non-specific (missing the target) activity (table 3).

[0319] Table 2. Luciferase activity in the liver 6 hours after intravenous administration of 0.5 mg / kg LNPs containing PEG-conjugated lipids or PEOZ-conjugated lipids in BALB / c mice (n=4)

[0320]

[0321] Table 3. Luciferase activity in spleen 6 hours after intravenous administration of 0.5 mg / kg LNPs containing PEG-conjugated lipids or PEOZ-conjugated lipids in BALB / c mice (n=4)

[0322]

[0323] To assess the immunostimulatory potential of these PEOZ formulations, MCP-1 induction was measured in plasma samples 6 hours after intravenous administration.PEOZ-based LNPs induced similar or lower cytokine levels compared to established PEGylated counterparts (Table 4).

[0324] Table 4. Induction of MCP-1 6 hours after intravenous administration of 0.5 mg / kg luciferase mRNA-LNPs containing PEG-conjugated lipids or PEOZ-conjugated lipids in BALB / c mice (n=4).

[0325]

[0326] Example 7. Effect of PEOZ-lipid on plasma clearance.

[0327] The LNP preparation of the PEOZ lipid carrying about 5000Da is compared with the benchmark control (PEG2000-C-DMA), to obtain the clearance rate of plasma after intravenous injection. The ionizable lipid level in the composition is used as the index of using mass spectrometry to evaluate the clearance rate. At the lipid of polymer conjugation: cationic lipid: cholesterol: under the LNP ratio of 1.6:54.6:32.8:10.9 of DPSC, compared with benchmark, the preparation (compound 11, compound 12, compound 13, compound 14 and compound 15) containing PEOZ shows the speed (table 5) of removing from blood plasma in 0.25 hour after injection of improvement. The shorter residence time shown in the plasma chamber by the LNPS containing PEOZ can potentially help alleviate the antibody response after repeated dose administration.

[0328] Table 5. Plasma clearance after intravenous injection of 0.5 mg / kg luciferase mRNA-LNPs containing PEG-conjugated lipids or PEOZ-conjugated lipids in BALB / c mice (n=4). Blood samples were collected at 15 minutes, 30 minutes, 1 hour, 3 hours and 6 hours after administration.

[0329]

[0330]

[0331] Example 8. Effect of PEOZ-lipid ratio and structure on particle properties.

[0332] The PEOZ lipid of about 5000Da with dialkyl C14 chain is mixed with LNP with various mol ratios (0.5%, 1.5% and 3.0%). Although PEOZ 5000 polymer has hydrophobicity, it is mixed into LNP and causes to form stable particle, and wherein size depends on the amount of PEOZ lipid. Particle size reduces (table 6) along with the increase of the amount of PEOZ lipid. For the fixed PEOZ lipid concentration of 1.5mol%, change PEOZ lipid chemistry and do not significantly affect particle characteristics (table 7). Generally speaking, these results show that the PEOZ preparation can be designed by the change of chain length and mol ratio.

[0333] Table 6. Particle properties of ovalbumin mRNA-LNP formulations titrated with PEOZ5000-DMA lipids

[0334]

[0335] %EE = encapsulation efficiency; PDI = polydispersity

[0336] Table 7. Particle properties of ovalbumin mRNA-LNP formulations containing PEOZ lipids

[0337]

[0338] %EE = encapsulation efficiency; PDI = polydispersity

[0339] Example 9. Effect of lipid ratio on the immunogenicity of ovalbumin model PEOZ-LNP.

[0340] The ability of LNP formulations containing different amounts of PEOZ5000 lipids to induce antigen-specific immunogenicity after intramuscular (IM) administration was evaluated in the ovalbumin (OVA) model. This model identifies the efficacy of the formulation in a vaccine setting. The formulations were compared to a PEG-lipid benchmark control.

[0341] Animals were treated with LNPs in the primary / boost scheme described in Example 4, and the level of anti-OVA IgG antibodies produced at the 35th day was then assessed. Compared to the baseline control, LNPs containing 0.5% PEOZ produced equivalent levels of anti-OVA IgG (Table 8). These trends were followed in the analysis of splenocytes for the production of interferon-γ (Table 9). Alternative PEOZ-lipid structures were also tested, and resulted in comparable levels of anti-OVA IgG levels (Table 10), as well as similar or higher levels of splenocytes producing interferon-γ compared to the baseline (Table 11).

[0342] These results suggest that LNPs containing PEOZ-lipids can be used to deliver mRNA encoding antigens, generate host immune responses against those antigens, and are therefore successfully incorporated into vaccine platforms. PEG is reported to be present in many other products, such as cosmetics, causing a small population to produce anti-PEG antibodies. When such individuals are exposed to PEG in the form of LNPs, such as coronavirus vaccines (Shimabukuro 2021), this may cause adverse reactions. Therefore, the ability to replace PEG lipids in LNPs with alternative polymer-conjugated lipids (e.g., PEOZ-lipids) has enormous utility.

[0343] Table 8. Anti-OVA IgG levels at day 35 following intramuscular administration of 1 μg dose of OVA mRNA LNPs at days 0 and 21 in BALB / c mice (n=4).

[0344]

[0345] Table 9. IFN-γ producing splenocytes on day 35 following intramuscular administration of 1 μg dose of OVA mRNA LNPs on days 0 and 21 in BALB / c mice (n=4).

[0346]

[0347]

[0348] Table 10. Anti-OVA IgG levels at day 35 following intramuscular administration of 1 μg dose of OVA mRNA LNPs at days 0 and 21 in BALB / c mice (n=4).

[0349]

[0350] Table 11. IFN-γ producing splenocytes on day 35 following intramuscular administration of 1 μg dose of OVA mRNA LNPs on days 0 and 21 in BALB / c mice (n=4).

[0351]

[0352] It should be understood that the above description is intended to be illustrative rather than restrictive. After reading the above description, many embodiments will be apparent to those skilled in the art. Therefore, the scope of the present invention should not be determined with reference to the above description, but should be determined with reference to the full range of the equivalents claimed by the attached claims and these claims. The disclosure of all articles and references (including patent applications, patents, PCT publications and Genbank registration numbers) is incorporated herein by reference for all purposes.

Claims

1. A poly(alkyloxazoline)-lipid conjugate according to formula I: or a pharmaceutically acceptable salt thereof, wherein: Subscript n is an integer from 10 to 100; R 1 Independently C 1-6 alkyl; Each R 2 are independently selected from hydrogen, C 1-6 Alkyl and C 1-6 acyl groups; and (i) Z is -S(CH2)2C(O)-, and R 3 Selected from -NR 3a R 3b 、-NR 3a CH2CH(R 3b )2、-CH(R 3b )2 and -CH2CH(R 3b )2; or (ii) Z is selected from -Z 1 -OC(O)-、-Z 1 -NHC(O)-、-Z 1 -S(O)2- and -Z 1 -OCH2-, Z 1 is selected from the group consisting of a covalent bond, an oligo(ethylene glycol) diradical and a poly(ethylene glycol) diradical, and R 3 Selected from -NR 3a R 3b and -CH(R 3b )2; Each R 3a and R 3b are independently selected from hydrogen, C 6-22 Alkyl, C 6-22 Alkenyl and C 6-22 Alkynyl, where R 3a and R 3b One or more non-adjacent CH2 groups in are optionally and independently replaced by oxygen, The condition is that at least one R 3a or R 3b Selected from C 6-22 Alkyl, C 6-22 Alkenyl and C 6-22 Alkynyl, where R 3a or R 3b One or more non-adjacent CH2 groups in are optionally and independently replaced by oxygen.

2. The poly(alkyloxazoline)-lipid conjugate or a pharmaceutically acceptable salt thereof according to claim 1, wherein R 1 It is ethyl.

3. The poly(alkyloxazoline)-lipid conjugate or a pharmaceutically acceptable salt thereof according to claim 1, wherein R 1 It's methyl.

4. The poly(alkyloxazoline)-lipid conjugate or a pharmaceutically acceptable salt thereof according to claim 1, wherein each R 1 Independently selected from ethyl and methyl. 5 . The poly(alkyloxazoline)-lipid conjugate or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the subscript n is an integer from about 15 to about 55.

6. The poly(alkyloxazoline)-lipid conjugate of claim 5, or a pharmaceutically acceptable salt thereof, wherein the poly(alkyloxazoline) portion of the conjugate has a number average molecular weight of about 2,000 Da to about 5,000 Da.

7. The poly(alkyloxazoline)-lipid conjugate according to any one of claims 1 to 6, having a structure according to Formula IIa: or a pharmaceutically acceptable salt thereof, wherein: R 2 is selected from hydrogen and methyl; R 3a Selected from hydrogen, C 12-18 Alkyl and C 12-18 alkenyl; and R 3b Selected from C 12-18 Alkyl and C 12-18 Alkenyl.

8. The poly(alkyloxazoline)-lipid conjugate of claim 7, wherein R 3a and R 3b Independently selected from C12-18 Alkyl and C 12-18 Alkenyl.

9. The poly(alkyloxazoline)-lipid conjugate according to any one of claims 1 to 6, having a structure according to formula IIb: or a pharmaceutically acceptable salt thereof, wherein: R 2 is selected from hydrogen and methyl; and Each R 3c Independently selected from C 12-18 Alkyl and C 12-18 Alkenyl.

10. The poly(alkyloxazoline)-lipid conjugate of any one of claims 1 to 6, wherein Z is -Z 1 -OC(O)-,Z 1 is selected from a covalent bond and a poly(ethylene glycol) diradical, and R 3 Yes - NR 3a R 3b .

11. The poly(alkyloxazoline)-lipid conjugate of any one of claims 1 to 6, wherein Z is -Z 1 -NHC(O)-,Z 1 is a covalent bond, and R 3 Yes - NR 3a R 3b .

12. The poly(alkyloxazoline)-lipid conjugate of any one of claims 1 to 6, wherein Z is 3 Yes-Z 1 -OC(O)-,Z 1 is a covalent bond, and R 3 Yes -CH(R 3b )2.

13. The poly(alkyloxazoline)-lipid conjugate of any one of claims 1 to 6, wherein Z is -Z 1 -S(O)2-,Z 1 is a covalent bond, and R 3 Yes - NR 3a R 3b .

14. The poly(alkyloxazoline)-lipid conjugate of any one of claims 1 to 6, wherein Z is -Z 1 -OCH2-, Z 1 is a covalent bond, and R 3 Yes -CH(R 3b )2.

15. The poly(alkyloxazoline)-lipid conjugate of any one of claims 1 to 6, wherein Z is -Z 1 -NHC(O)-,Z 1is a covalent bond, and R 3 Yes -CH(R 3b )2.

16. The poly(alkyloxazoline)-lipid conjugate according to any one of claims 10 to 15, wherein R 3a and each R 3b Independently selected from C 12-18 Alkyl and C 12-18 Alkenyl.

17. A lipid nanoparticle comprising the poly(alkyloxazoline)-lipid conjugate of any one of claims 1 to 16.

18. The lipid nanoparticle of claim 17, further comprising a cationic lipid, a neutral lipid, a sterol or a combination thereof.

19. The lipid nanoparticle according to claim 17 or 18, further comprising a nucleic acid.

20. A lipid nanoparticle comprising: (a) nucleic acids; (b) a cationic lipid, said cationic lipid accounting for 30 mol % to 80 mol % of the total lipids present in said lipid nanoparticle; (c) neutral lipids; (d) sterols; and (e) a poly(alkyloxazoline)-lipid conjugate, wherein the poly(alkyloxazoline)-lipid conjugate accounts for 0.1 mol% to 10 mol% of the total lipids present in the lipid nanoparticle.

21. The lipid nanoparticle of claim 20, wherein the cationic lipid accounts for 40 mol% to 70 mol% of the total lipids present in the lipid nanoparticle.

22. The lipid nanoparticle of claim 20 or 21, wherein the cationic lipid accounts for 45 mol% to 65 mol% of the total lipids present in the lipid nanoparticle.

23. The lipid nanoparticle according to any one of claims 20 to 22, wherein the cationic lipid accounts for 45 mol% to 60 mol% of the total lipids present in the lipid nanoparticle.

24. The lipid nanoparticle according to any one of claims 20 to 23, wherein the cationic lipid accounts for 50 mol% to 60 mol% of the total lipids present in the lipid nanoparticle.

25. The lipid nanoparticle according to any one of claims 20 to 24, wherein the neutral lipid accounts for 3 mol% to 20 mol% of the total lipids present in the lipid nanoparticle.

26. The lipid nanoparticle according to any one of claims 20 to 25, wherein the neutral lipid accounts for 5 mol% to 15 mol% of the total lipids present in the lipid nanoparticle.

27. The lipid nanoparticle according to any one of claims 20 to 26, wherein the neutral lipid accounts for 8 mol% to 12 mol% of the total lipids present in the lipid nanoparticle.

28. The lipid nanoparticle according to any one of claims 20 to 27, wherein the sterol accounts for 10 mol% to 60 mol% of the total lipids present in the lipid nanoparticle.

29. The lipid nanoparticle according to any one of claims 20 to 28, wherein the sterol accounts for 20 mol% to 50 mol% of the total lipids present in the lipid nanoparticle.

30. The lipid nanoparticle according to any one of claims 20 to 29, wherein the sterol accounts for 30 mol% to 40 mol% of the total lipids present in the lipid nanoparticle.

31. The lipid nanoparticle of any one of claims 20 to 30, wherein the poly(alkyloxazoline)-lipid conjugate comprises 0.1 mol% to 5 mol% of the total lipid present in the lipid nanoparticle.

32. The lipid nanoparticle of any one of claims 20 to 31, wherein the poly(alkyloxazoline)-lipid conjugate comprises 0.5 mol% to 3 mol% of the total lipid present in the lipid nanoparticle.

33. The lipid nanoparticle of claim 20, wherein the cationic lipid accounts for 50 to 60 mol% of the total lipids present in the lipid nanoparticle, the neutral lipid accounts for 8 to 12 mol% of the total lipids present in the lipid nanoparticle, the sterol accounts for 30 to 40 mol% of the total lipids present in the lipid nanoparticle, and the poly(alkyloxazoline)-lipid conjugate accounts for 0.5 to 3 mol% of the total lipids present in the lipid nanoparticle.

34. A lipid nanoparticle according to any one of claims 20 to 33, wherein the neutral lipid comprises a phospholipid.

35. The lipid nanoparticle of any one of claims 20 to 34, wherein the sterol comprises cholesterol.

36. The lipid nanoparticle of any one of claims 20 to 35, wherein the poly(alkyloxazoline)-lipid conjugate comprises the poly(alkyloxazoline)-lipid conjugate of any one of claims 1 to 16.

37. A lipid nanoparticle according to any one of claims 19 to 35, wherein the nucleic acid comprises RNA.

38. A lipid nanoparticle according to claim 37, wherein the RNA comprises mRNA.

39. The lipid nanoparticle of any one of claims 19 to 38, wherein the nucleic acid is completely encapsulated in the lipid nanoparticle.

40. The lipid nanoparticle of any one of claims 17 to 39, wherein the lipid nanoparticle has an average diameter of 40 nm to 150 nm.

41. A pharmaceutical composition comprising the lipid nanoparticle of any one of claims 17 to 40 and a pharmaceutically acceptable carrier.

42. The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is formulated for intravenous administration, intramuscular administration, pulmonary administration, intracerebral administration, intrathecal administration, or intranasal administration.

43. A method for introducing a nucleic acid into a cell, the method comprising: The cell is contacted with the lipid nanoparticle of any one of claims 17 to 40 or the pharmaceutical composition of claim 41 or 42.

44. A method for delivering a nucleic acid to a subject, the method comprising: The lipid nanoparticle of any one of claims 17 to 40 or the pharmaceutical composition of claim 41 or 42 is administered to a subject.

45. A method for preventing or treating a disease or condition in a subject in need thereof, the method comprising: The lipid nanoparticle of any one of claims 17 to 40 or the pharmaceutical composition of claim 41 or 42 is administered to a subject.

46. ​​The method of claim 45, wherein the disease or disorder is a viral infection, a liver disease or disorder, a lung disease or disorder, a disease or disorder of the CNS, or cancer.